

# STN Columbus

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
 NEWS 2 JUL 02 LMEDLINE coverage updated  
 NEWS 3 JUL 02 SCISEARCH enhanced with complete author names  
 NEWS 4 JUL 02 CHEMCATS accession numbers revised  
 NEWS 5 JUL 02 CA/CAPplus enhanced with utility model patents from China  
 NEWS 6 JUL 16 CAPplus enhanced with French and German abstracts  
 NEWS 7 JUL 18 CA/CAPplus patent coverage enhanced  
 NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
 NEWS 9 JUL 30 USGENE now available on STN  
 NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
 NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition  
 NEWS 12 AUG 13 CA/CAPplus enhanced with additional kind codes for granted patents  
 NEWS 13 AUG 20 CA/CAPplus enhanced with CAS indexing in pre-1907 records  
 NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
 NEWS 15 AUG 27 USPATOLD now available on STN  
 NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
 NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
 NEWS 18 SEP 13 FORIS renamed to SOFIS  
 NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
 NEWS 20 SEP 17 CA/CAPplus enhanced with printed CA page images from 1967-1998  
 NEWS 21 SEP 17 CAPplus coverage extended to include traditional medicine patents  
 NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
 NEWS 23 OCT 02 CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt  
 NEWS 24 OCT 19 BEILSTEIN updated with new compounds  
 NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced  
 NEWS 26 NOV 19 WPIX enhanced with XML display format  
 NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 20:43:58 ON 20 NOV 2007

=> file uspatall		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'USPATFULL' ENTERED AT 20:44:20 ON 20 NOV 2007  
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 20:44:20 ON 20 NOV 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:44:20 ON 20 NOV 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (controlled release? oral dosage form or sustained release oral dosage form)  
L1 430 (CONTROLLED RELEASE? ORAL DOSAGE FORM OR SUSTAINED RELEASE ORAL  
DOSAGE FORM)

=> s (controlled release? oral dosage form or sustained release oral dosage form)/clm  
L2 128 (CONTROLLED RELEASE? ORAL DOSAGE FORM OR SUSTAINED RELEASE ORAL  
DOSAGE FORM)/CLM

=> s polymer  
L3 742885 POLYMER

=> s polymer/clm  
L4 254898 POLYMER/CLM

=> s l1 and l3  
L5 398 L1 AND L3

=> s l2 and l4  
L6 77 L2 AND L4

=> d 1-77

L6 ANSWER 1 OF 77 USPATFULL on STN

Full Text

AN 2007:277824 USPATFULL  
TI NOVEL DRUG COMPOSITIONS AND DOSAGE FORMS OF TOPIRAMATE  
IN Edgren, David, Los Altos, CA, UNITED STATES  
Jao, Frank, San Jose, CA, UNITED STATES  
Kimbrel, Rhea, Mountain View, CA, UNITED STATES  
Shivanand, Padmaja, Los Altos, CA, UNITED STATES  
Ayer, Atul Devdatt, Palo Alto, CA, UNITED STATES  
Bhatti, Gurdish, Freemont, CA, UNITED STATES  
Lam, Andrew, San Jose, CA, UNITED STATES  
Li, Shu, Union City, CA, UNITED STATES  
Skruzacek, Robert, Newark, CA, UNITED STATES  
To, Winnie, San Jose, CA, UNITED STATES  
Wong, Patrick S.L., Burlingame, CA, UNITED STATES  
Li, Shaoling, Sunnyvale, CA, UNITED STATES  
Yam, Noyomi, Sunnyvale, CA, UNITED STATES  
Seroff, Sylvia Lillian, San Jose, CA, UNITED STATES  
PI US 2007243254 A1 20071018  
AI US 2007-737829 A1 20070628 (11)  
RLI Continuation-in-part of Ser. No. US 2004-24378, filed on 28 Dec 2004,  
ABANDONED Continuation-in-part of Ser. No. US 2004-24330, filed on 28  
Dec 2004, PENDING Continuation-in-part of Ser. No. US 2003-628970, filed  
on 28 Jul 2003, PENDING Continuation-in-part of Ser. No. US 2003-606575,  
filed on 26 Jun 2003, PENDING  
PRAI US 2003-533451P 20031229 (60)  
US 2003-533112P 20031229 (60)  
US 2002-399993P 20020729 (60)  
US 2003-468519P 20030507 (60)  
US 2002-392128P 20020626 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4469  
INCL INCLM: 424/471.000  
NCL NCLM: 424/471.000  
IC IPCI A61K0009-24 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A];  
A61P0025-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 77 USPATFULL on STN

Full Text

AN 2007:236829 USPATFULL  
TI Oral controlled release formulation for sedative and hypotnic agents  
IN Cheng, Xiu Xiu, Weston, FL, UNITED STATES  
Tian, Dacheng, Miramar, FL, UNITED STATES

PA Xiu Xiu Cheng and Dacheng Tian (U.S. corporation)  
 PI US 2007207203 A1 20070906  
 AI US 2007-712133 A1 20070228 (11)  
 PRAI US 2006-778346P 20060302 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 913  
 INCL INCLM: 424/457.000  
 INCLS: 424/400.000; 424/468.000  
 NCL NCLM: 424/457.000  
 NCLS: 424/400.000; 424/468.000  
 IC IPCI A61K0009-52 [I,A]; A61K0009-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 77 USPATFULL on STN

Full Text

AN 2007:224385 USPATFULL  
 TI Sustained release torsemide dosage forms  
 IN Sanghvi, Pradeep, Schererville, IN, UNITED STATES  
 Ketsela, Sara, Danbury, CT, UNITED STATES  
 Sciascia, Thomas, Belmont, MA, UNITED STATES  
 Jaworski, Theodore Joseph, Cary, NC, UNITED STATES  
 PA Penwest Pharmaceuticals Co., Patterson, NY, UNITED STATES (U.S. corporation)  
 PI US 2007196482 A1 20070823  
 AI US 2006-640083 A1 20061215 (11)  
 PRAI US 2005-750961P 20051216 (60)  
 US 2005-751847P 20051220 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2330  
 INCL INCLM: 424/468.000  
 INCLS: 514/346.000  
 NCL NCLM: 424/468.000  
 NCLS: 514/346.000  
 IC IPCI A61K0009-22 [I,A]; A61K0031-44 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 77 USPATFULL on STN

Full Text

AN 2007:217174 USPATFULL  
 TI Sustained release dosage forms of ziprasidone  
 IN Ahmed, Imran, East Lyme, CT, UNITED STATES  
 Appel, Leah Elizabeth, Bend, OR, UNITED STATES  
 Babcock, Walter Christian, Bend, OR, UNITED STATES  
 Friesen, Dwayne Thomas, Bend, OR, UNITED STATES  
 Herbig, Scott, East Lyme, CT, UNITED STATES  
 Lyon, David Keith, Bend, OR, UNITED STATES  
 Shamblin, Sheri L., North Stonington, CT, UNITED STATES  
 Shanker, Ravi Mysore, Groton, CT, UNITED STATES  
 Smithey, Daniel Tod, Bend, OR, UNITED STATES  
 Sutton, Steven C., Niantic, CT, UNITED STATES  
 Thombre, Avinash G., East Lyme, CT, UNITED STATES  
 Waterman, Kenneth C., Waterford, CT, UNITED STATES  
 PA Pfizer Inc. (U.S. corporation)  
 PI US 2007190129 A1 20070816  
 AI US 2004-931143 A1 20040831 (10)  
 PRAI US 2003-499484P 20030902 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3724  
 INCL INCLM: 424/451.000  
 INCLS: 514/255.050  
 NCL NCLM: 424/451.000  
 NCLS: 514/255.050  
 IC IPCI A61K0009-48 [I,A]; A61K0031-4965 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 77 USPATFULL on STN

Full Text

AN 2007:56680 USPATFULL  
 TI Treating premature ejaculation using gabapentin and pregabalin prodrugs

IN Tran, Pierre V., San Jose, CA, UNITED STATES  
 PI US 2007049626 A1 20070301  
 AI US 2006-507642 A1 20060822 (11)  
 PRAI US 2005-711477P 20050826 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1967  
 INCL INCLM: 514/357.000  
 INCLS: 514/483.000; 514/408.000  
 NCL NCLM: 514/357.000  
 NCLS: 514/408.000; 514/483.000  
 IC IPCI A61K0031-325 [I,A]; A61K0031-40 [I,A]; A61K0031-44 [I,A]  
 IPCR A61K0031-325 [I,C]; A61K0031-325 [I,A]; A61K0031-40 [I,C];  
 A61K0031-40 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 77 USPATFULL on STN

Full Text

AN 2006:267731 USPATFULL  
 TI Controlled release venlafaxine formulations  
 IN Ketsela, Sara, Danbury, CT, UNITED STATES  
 Dinicola, Dean, Warren, CT, UNITED STATES  
 Baichwal, Anand R., Wappingers Falls, NY, UNITED STATES  
 PA Penwest Pharmaceuticals Co., Patterson, NY, UNITED STATES (U.S.  
 corporation)  
 PI US 2006228413 A1 20061012  
 AI US 2006-363845 A1 20060228 (11)  
 PRAI US 2005-657035P 20050228 (60)  
 US 2005-750594P 20051214 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2452  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC IPCI A61K0009-22 [I,A]  
 IPCR A61K0009-22 [I,C]; A61K0009-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 77 USPATFULL on STN

Full Text

AN 2006:227548 USPATFULL  
 TI Controlled release O-desmethylvenlafaxine formulations  
 IN Ketsela, Sara, Danbury, CT, UNITED STATES  
 Dinicola, Dean, Warren, CT, UNITED STATES  
 Baichwal, Anand R., Wappingers Falls, NY, UNITED STATES  
 PA Penwest Pharmaceuticals Co., Patterson, NY, UNITED STATES (U.S.  
 corporation)  
 PI US 2006193912 A1 20060831  
 AI US 2006-363842 A1 20060228 (11)  
 PRAI US 2005-657035P 20050228 (60)  
 US 2005-750594P 20051214 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1466  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC IPCI A61K0009-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 77 USPATFULL on STN

Full Text

AN 2006:174084 USPATFULL  
 TI Sustained release compositions containing alfuzosin  
 IN Viswanathan, Narayanan Badri, Madipakkam, INDIA  
 Ramakrishnan, Sankar, Thajavur districk, INDIA  
 Raghuvanshi, Rajeev Singh, New Delhi, INDIA  
 Rampal, Ashok, Amritsar, INDIA  
 PI US 2006147530 A1 20060706  
 AI US 2003-532296 A1 20031022 (10)  
 WO 2003-IB4677 20031022  
 20060206 PCT 371 date  
 PRAI IN 2002-10232002 20021022

DT Utility  
 FS APPLICATION  
 LN.CNT 735  
 INCL INCLM: 424/470.000  
 NCL NCLM: 424/470.000  
 IC IPCI A61K0009-26 [I,A]  
 IPCR A61K0009-26 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-26 [I,C]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A];  
 A61K0031-185 [I,C\*]; A61K0031-195 [I,A]; A61K0031-517 [I,C\*];  
 A61K0031-517 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 77 USPATFULL on STN

Full Text

AN 2006:166531 USPATFULL  
 TI HMG-CoA reductase inhibitor extended release formulation  
 IN Chen, Chih-Ming, Davie, FL, UNITED STATES  
 Chou, Joseph, Coral Springs, FL, UNITED STATES  
 Wong, David, Hollywood, FL, UNITED STATES  
 PA Andrx Labs LLC, Plantation, FL, UNITED STATES (U.S. corporation)  
 PI US 2006141036 A1 20060629  
 AI US 2006-355771 A1 20060216 (11)  
 RLI Continuation of Ser. No. US 1999-435576, filed on 8 Nov 1999, PENDING  
 Continuation-in-part of Ser. No. US 1999-339494, filed on 24 Jun 1999,  
 ABANDONED Continuation of Ser. No. US 1997-989253, filed on 12 Dec 1997,  
 GRANTED, Pat. No. US 5916595

DT Utility  
 FS APPLICATION

LN.CNT 1742  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC IPCI A61K0009-22 [I,A]  
 IPCR A61K0009-22 [I,A]; A61K0009-00 [I,C\*]; A61K0009-00 [I,A];  
 A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C];  
 A61K0009-28 [I,C\*]; A61K0009-28 [I,A]; A61K0031-21 [I,C\*];  
 A61K0031-22 [I,A]; A61K0031-366 [I,C\*]; A61K0031-366 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 77 USPATFULL on STN

Full Text

AN 2006:166530 USPATFULL  
 TI HMG-COA reductase inhibitor extended release formulation  
 IN Chen, Chih-Ming, Davie, FL, UNITED STATES  
 Chou, Joseph, Coral Springs, FL, UNITED STATES  
 Wong, David, Hollywood, FL, UNITED STATES  
 PA Andrx Labs LLC, Plantation, FL, UNITED STATES (U.S. corporation)  
 PI US 2006141035 A1 20060629  
 AI US 2006-355335 A1 20060216 (11)  
 RLI Continuation of Ser. No. US 1999-435576, filed on 8 Nov 1999, PENDING  
 Continuation-in-part of Ser. No. US 1999-339494, filed on 24 Jun 1999,  
 ABANDONED Continuation of Ser. No. US 1997-989253, filed on 12 Dec 1997,  
 GRANTED, Pat. No. US 5916595

DT Utility  
 FS APPLICATION

LN.CNT 1721  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC IPCI A61K0009-22 [I,A]  
 IPCR A61K0009-22 [I,A]; A61K0009-00 [I,C\*]; A61K0009-00 [I,A];  
 A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C];  
 A61K0009-28 [I,C\*]; A61K0009-28 [I,A]; A61K0031-21 [I,C\*];  
 A61K0031-22 [I,A]; A61K0031-366 [I,C\*]; A61K0031-366 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 77 USPATFULL on STN

Full Text

AN 2006:166529 USPATFULL  
 TI GABA analog prodrug sustained release oral dosage forms  
 IN Cundy, Kenneth C., Redwood City, CA, UNITED STATES  
 Sastry, Srikonda, Sunnyvale, CA, UNITED STATES  
 Leung, Manshiu, Daly City, CA, UNITED STATES  
 Kadri, Balaji V., Tampa, FL, UNITED STATES

Stach, Paul E., Plymouth, MN, UNITED STATES  
PA XenoPort, Inc. (U.S. corporation)  
PI US 2006141034 A1 20060629  
AI US 2005-269045 A1 20051103 (11)  
PRAI US 2004-625737P 20041104 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1257  
INCL INCLM: 424/468.000  
INCLS: 514/548.000  
NCL NCLM: 424/468.000  
NCLS: 514/548.000  
IC IPCI A61K0009-22 [I,A]; A61K0031-225 [I,A]; A61K0031-21 [I,C\*]  
IPCR A61K0009-22 [I,A]; A61K0009-22 [I,C]; A61K0031-21 [I,C];  
A61K0031-225 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 77 USPATFULL on STN

Full Text

AN 2006:9678 USPATFULL  
TI Controlled release metformin compositions  
IN Chen, Chih-Ming, Davie, FL, UNITED STATES  
Cheng, Xiu-Xiu, Weston, FL, UNITED STATES  
Jan, Steve, Coral Springs, FL, UNITED STATES  
Chou, Joseph, Manassas, VA, UNITED STATES  
PA Andrx Corporation, Plantation, FL, UNITED STATES (U.S. corporation)  
PI US 2006008526 A1 20060112  
AI US 2005-225742 A1 20050913 (11)  
RLI Continuation of Ser. No. US 2004-796411, filed on 9 Mar 2004, PENDING  
Continuation of Ser. No. US 2000-705630, filed on 3 Nov 2000, GRANTED,  
Pat. No. US 6866866  
DT Utility  
FS APPLICATION  
LN.CNT 1228  
INCL INCLM: 424/468.000  
NCL NCLM: 424/468.000  
IC IPCI A61K0009-22 [I,A]  
IPCR A61K0009-22 [I,A]; A61K0009-22 [I,C]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 77 USPATFULL on STN

Full Text

AN 2006:9676 USPATFULL  
TI Controlled release metformin compositions  
IN Chen, Chih-Ming, Davie, FL, UNITED STATES  
Cheng, Xiu-Xiu, Weston, FL, UNITED STATES  
Jan, Steve, Coral Springs, FL, UNITED STATES  
Chou, Joseph, Manassas, VA, UNITED STATES  
PA Andrx Corporation, Plantation, FL, UNITED STATES (U.S. corporation)  
PI US 2006008524 A1 20060112  
AI US 2005-224785 A1 20050913 (11)  
RLI Continuation of Ser. No. US 2004-796411, filed on 9 Mar 2004, PENDING  
Continuation of Ser. No. US 2000-705630, filed on 3 Nov 2000, GRANTED,  
Pat. No. US 6866866  
DT Utility  
FS APPLICATION  
LN.CNT 1241  
INCL INCLM: 424/468.000  
NCL NCLM: 424/468.000  
IC IPCI A61K0009-22 [I,A]  
IPCR A61K0009-22 [I,A]; A61K0009-22 [I,C]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 77 USPATFULL on STN

Full Text

AN 2005:318111 USPATFULL  
TI Controlled release sodium valproate formulation  
IN Podhipleux, Nilobon, Weston, FL, UNITED STATES  
Cheng, Xiu Xiu, Weston, FL, UNITED STATES  
Lodin, Unchalee, North Miami Beach, FL, UNITED STATES  
Chen, Chih-Ming, Taipei, TAIWAN, PROVINCE OF CHINA  
Nangia, Avinash, Weston, FL, UNITED STATES

Tian, Dacheng, Miramar, FL, UNITED STATES  
 PI US 2005276850 A1 20051215  
 AI US 2004-868286 A1 20040615 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1068  
 INCL INCLM: 424/468.000  
 INCLS: 514/557.000  
 NCL NCLM: 424/468.000  
 NCLS: 514/557.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K031-19  
 IPCI A61K0009-22 [ICM,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C\*]  
 IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0031-185 [I,C\*];  
 A61K0031-19 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 77 USPATFULL on STN

Full Text

AN 2005:318110 USPATFULL  
 TI Sustained release dosage forms  
 IN Podhipleux, Nilobon, Weston, FL, UNITED STATES  
 Lodin, Unchalee, North Miami Beach, FL, UNITED STATES  
 Chen, Chih-Ming, Taipei, TAIWAN, PROVINCE OF CHINA  
 Nangia, Avinash, Weston, FL, UNITED STATES  
 PI US 2005276849 A1 20051215  
 AI US 2004-868285 A1 20040615 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1052  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-50  
 IPCI A61K0009-22 [ICM,7]; A61K0009-50 [ICS,7]  
 IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-50 [I,C\*];  
 A61K0009-50 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 77 USPATFULL on STN

Full Text

AN 2005:318109 USPATFULL  
 TI Sustained release neutralized divalproex sodium  
 IN Podhipleux, Nilobon, Weston, FL, UNITED STATES  
 Cheng, Xiu Xiu, Weston, FL, UNITED STATES  
 Lodin, Unchalee, North Miami Beach, FL, UNITED STATES  
 Chen, Chih-Ming, Taipei, TAIWAN, PROVINCE OF CHINA  
 Nangia, Avinash, Weston, FL, UNITED STATES  
 Tian, Dacheng, Miramar, FL, UNITED STATES  
 PI US 2005276848 A1 20051215  
 AI US 2004-867799 A1 20040615 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 784  
 INCL INCLM: 424/468.000  
 INCLS: 514/557.000  
 NCL NCLM: 424/468.000  
 NCLS: 514/557.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-20; A61K031-19  
 IPCI A61K0009-22 [ICM,7]; A61K0009-20 [ICS,7]; A61K0031-19 [ICS,7];  
 A61K0031-185 [ICS,7,C\*]  
 IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 77 USPATFULL on STN

Full Text

AN 2005:221616 USPATFULL

TI Treating or preventing restless legs syndrome using prodrugs of GABA analogs  
 IN Barrett, Ronald W., Saratoga, CA, UNITED STATES  
 Canafax, Daniel M., Half Moon Bay, CA, UNITED STATES  
 PI US 2005192353 A1 20050901  
 AI US 2004-969196 A1 20040917 (10)  
 PRAI US 2003-504172P 20030917 (60)  
 US 2003-504279P 20030918 (60)  
 US 2004-538495P 20040122 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2678  
 INCL INCLM: 514/561.000  
 NCL NCLM: 514/561.000  
 IC [7]  
 ICM A61K031-195  
 IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]  
 IPCR A61K0031-185 [I,C\*]; A61K0031-195 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 77 USPATFULL on STN

Full Text

AN 2005:195851 USPATFULL  
 TI Methods and dosage forms for increasing solubility of drug compositions for controlled delivery  
 IN Jao, Frank, San Jose, CA, UNITED STATES  
 Edgren, David E., Los Altos, CA, UNITED STATES  
 Skluzacek, Robert R., Newark, CA, UNITED STATES  
 Yam, Noymi V., Sunnyvale, CA, UNITED STATES  
 PI US 2005169992 A1 20050804  
 AI US 2004-23257 A1 20041222 (11)  
 PRAI US 2003-532450P 20031223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2545  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-24  
 IPCI A61K0009-22 [ICM,7]; A61K0009-24 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 77 USPATFULL on STN

Full Text

AN 2005:195850 USPATFULL  
 TI Sustained release torsemide dosage forms  
 IN Sanghvi, Pradeep, Schererville, IN, UNITED STATES  
 Ketsela, Sara, Danbury, CT, UNITED STATES  
 Sciascia, Thomas, Belmont, MA, UNITED STATES  
 Jaworski, Theodore Joseph, Cary, NC, UNITED STATES  
 PA Penwest Pharmaceuticals Co., Patterson, NY, UNITED STATES (U.S. corporation)  
 PI US 2005169991 A1 20050804  
 AI US 2004-9800 A1 20041210 (11)  
 PRAI US 2003-529138P 20031212 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1866  
 INCL INCLM: 424/468.000  
 INCLS: 514/054.000  
 NCL NCLM: 424/468.000  
 NCLS: 514/054.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K031-736  
 IPCI A61K0009-22 [ICM,7]; A61K0031-736 [ICS,7]  
 IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0031-736 [I,C\*]; A61K0031-736 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L6 ANSWER 20 OF 77 USPATFULL on STN

Full Text

AN 2005:195849 USPATFULL  
TI Controlled release dosage forms using acrylic polymer, and process for making  
IN Kao, Huai-Hung, Syosset, NY, UNITED STATES  
Zeng, Yadi, Fort Lee, NJ, UNITED STATES  
Jim, Fai, Franklin Square, NY, UNITED STATES  
Chang, Sou-Chan, Westbury, NY, UNITED STATES  
PI US 2005169990 A1 20050804  
AI US 2004-501798 A1 20040719 (10)  
RLI Continuation of Ser. No. WO 2002-US18088, filed on 7 Jun 2002, PENDING  
PRAI US 2001-297150P 20010608 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 433  
INCL INCLM: 424/468.000  
INCLS: 514/282.000; 264/109.000  
NCL NCLM: 424/468.000  
NCLS: 264/109.000; 514/282.000  
IC [7]  
ICM A61K031-485  
ICS A61K009-22  
IPCI A61K0031-485 [ICM,7]; A61K0009-22 [ICS,7]  
IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 77 USPATFULL on STN

Full Text

AN 2005:188933 USPATFULL  
TI Rosiglitazone and metformin formulations  
IN Boehm, Garth, Westfield, NJ, UNITED STATES  
Dundon, Josephine, Fanwood, NJ, UNITED STATES  
PI US 2005163842 A1 20050728  
AI US 2004-21562 A1 20041223 (11)  
PRAI US 2003-533781P 20031231 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3119  
INCL INCLM: 424/468.000  
INCLS: 514/369.000  
NCL NCLM: 424/468.000  
NCLS: 514/369.000  
IC [7]  
ICM A61K031-426  
ICS A61K009-22  
IPCI A61K0031-426 [ICM,7]; A61K0009-22 [ICS,7]  
IPCR A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 77 USPATFULL on STN

Full Text

AN 2005:188928 USPATFULL  
TI Rosiglitazone formulations  
IN Boehm, Garth, Westfield, NJ, UNITED STATES  
Dundon, Josephine, Fanwood, NJ, UNITED STATES  
PI US 2005163837 A1 20050728  
AI US 2004-21491 A1 20041223 (11)  
PRAI US 2003-533856P 20031231 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3004  
INCL INCLM: 424/464.000  
INCLS: 514/369.000; 424/486.000  
NCL NCLM: 424/464.000  
NCLS: 424/486.000; 514/369.000  
IC [7]  
ICM A61K031-426  
ICS A61K009-20; A61K009-14  
IPCI A61K0031-426 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-14 [ICS,7]

IPCR A61K0009-14 [N,C\*]; A61K0009-14 [N,A]; A61K0009-16 [N,C\*];  
A61K0009-16 [N,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
A61K0009-24 [I,C\*]; A61K0009-24 [I,A]; A61K0009-28 [N,C\*];  
A61K0009-28 [N,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 77 USPATFULL on STN

Full Text

AN 2005:183000 USPATFULL  
TI Quetiapine formulations  
IN Boehm, Garth, Westfield, NJ, UNITED STATES  
Dundon, Josephine, Fanwood, NJ, UNITED STATES  
PI US 2005158383 A1 20050721  
AI US 2004-970850 A1 20041021 (10)  
PRAI US 2003-513461P 20031021 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3736  
INCL INCLM: 424/468.000  
INCLS: 424/484.000; 514/211.130  
NCL NCLM: 424/468.000  
NCLS: 424/484.000; 514/211.130  
IC [7]  
ICM A61K031-554  
ICS A61K009-48; A61K009-22; A61K009-14  
IPCI A61K0031-554 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-22 [ICS,7];  
A61K0009-14 [ICS,7]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-24 [I,C\*];  
A61K0009-24 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 77 USPATFULL on STN

Full Text

AN 2005:176894 USPATFULL  
TI Atomoxetine formulations  
IN Boehm, Garth, Westfield, NJ, UNITED STATES  
Dundon, Josephine, Fanwood, NJ, UNITED STATES  
PI US 2005152974 A1 20050714  
AI US 2004-22338 A1 20041223 (11)  
PRAI US 2003-533517P 20031231 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3903  
INCL INCLM: 424/464.000  
INCLS: 424/490.000  
NCL NCLM: 424/464.000  
NCLS: 424/490.000  
IC [7]  
ICM A61K009-20  
ICS A61K009-24; A61K009-16; A61K009-50  
IPCI A61K0009-20 [ICM,7]; A61K0009-24 [ICS,7]; A61K0009-16 [ICS,7];  
A61K0009-50 [ICS,7]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]; A61K0009-24 [I,C\*]; A61K0009-24 [I,A];  
A61K0009-50 [I,C\*]; A61K0009-50 [I,A]; A61K0031-135 [I,C\*];  
A61K0031-135 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 77 USPATFULL on STN

Full Text

AN 2005:157900 USPATFULL  
TI Stepwise delivery of topiramate over prolonged period of time  
IN Yam, Noyomi V., Sunnyvale, CA, UNITED STATES  
Shivanand, Padmaja, Los Altos, CA, UNITED STATES  
Kimbel, Rhea, Mountain View, CA, UNITED STATES  
Allphin, Clark P., Mountain View, CA, UNITED STATES  
Wong, Patrick S.L., Burlingame, CA, UNITED STATES  
PI US 2005136108 A1 20050623  
AI US 2004-920934 A1 20040818 (10)  
PRAI US 2003-497162P 20030822 (60)  
DT Utility  
FS APPLICATION

LN.CNT 2090  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]  
 IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 77 USPATFULL on STN

Full Text

AN 2005:105612 USPATFULL  
 TI Treating and/or preventing urinary incontinence using prodrugs of GABA analogs  
 IN Barrett, Ronald W., Saratoga, CA, UNITED STATES  
 PI US 2005090550 A1 20050428  
 AI US 2004-940884 A1 20040913 (10)  
 PRAI US 2003-502585P 20030911 (60)  
 US 2003-505210P 20030922 (60)  
 US 2003-512288P 20031017 (60)  
 US 2004-538748P 20040122 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2744  
 INCL INCLM: 514/561.000  
 NCL NCLM: 514/561.000  
 IC [7]  
 ICM A61K031-47  
 ICS A61K031-195  
 IPCI A61K0031-47 [ICM,7]; A61K0031-195 [ICS,7]; A61K0031-185 [ICS,7,C\*]  
 IPCR A61K0031-185 [I,C\*]; A61K0031-195 [I,A]; A61K0031-47 [I,C\*]; A61K0031-47 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 77 USPATFULL on STN

Full Text

AN 2005:81146 USPATFULL  
 TI Novel drug compositions and dosage forms of topiramate  
 IN Modi, Nishit Bachulal, Sunnyvale, CA, UNITED STATES  
 Gupta, Suneel Kumar, Sunnyvale, CA, UNITED STATES  
 PI US 2005069587 A1 20050331  
 AI US 2004-930917 A1 20040831 (10)  
 PRAI US 2003-499783P 20030902 (60)  
 US 2004-538936P 20040123 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4577  
 INCL INCLM: 424/473.000  
 INCLS: 514/023.000  
 NCL NCLM: 424/473.000  
 NCLS: 514/023.000  
 IC [7]  
 ICM A61K009-48  
 ICS A61K009-24  
 IPCI A61K0009-48 [ICM,7]; A61K0009-24 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-35 [I,C\*]; A61K0031-35 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 77 USPATFULL on STN

Full Text

AN 2004:321689 USPATFULL  
 TI Amino acid conjugates providing for sustained systemic concentrations of gaba analogues  
 IN Gallop, Mark, Los Altos, CA, UNITED STATES  
 Cundy, Kenneth C, Redwood City, CA, UNITED STATES  
 Scheuerman, Randall A, Santa Clara, CA, UNITED STATES  
 Barrett, Ronald W, Saratoga, CA, UNITED STATES  
 Zerangue, Noa, San Carlos, CA, UNITED STATES  
 PI US 2004254344 A1 20041216  
 AI US 2004-480293 A1 20040713 (10)

WO 2002-US18493 20020611  
PRAI US 2001-297732P 20010611 (60)  
US 2002-364619P 20020318 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3913  
INCL INCLM: 530/331.000  
INCLS: 560/041.000; 560/155.000  
NCL NCLM: 530/331.000  
NCLS: 560/041.000; 560/155.000  
IC [7]  
ICM C07D229-02  
ICS C07K005-04  
IPCI C07D0229-02 [ICM,7]; C07D0229-00 [ICM,7,C\*]; C07K0005-04 [ICS,7];  
C07K0005-00 [ICS,7,C\*]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,A]; A61K0047-48 [I,C\*];  
A61K0047-48 [I,A]; C07C0237-00 [I,C\*]; C07C0237-12 [I,A];  
C07C0237-20 [I,A]; C07C0317-00 [I,C\*]; C07C0317-50 [I,A];  
C07C0323-00 [I,C\*]; C07C0323-59 [I,A]; C07C0323-60 [I,A];  
C07D0207-00 [I,C\*]; C07D0207-16 [I,A]; C07D0229-00 [I,C\*];  
C07D0229-02 [I,A]; C07D0233-00 [I,C\*]; C07D0233-54 [I,A];  
C07K0005-00 [I,C\*]; C07K0005-02 [I,A]; G01N0033-566 [I,C\*];  
G01N0033-566 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 77 USPATFULL on STN

Full Text

AN 2004:321591 USPATFULL  
TI Treating or preventing hot flashes using prodrugs of GABA analogs  
IN Barrett, Ronald W., Saratoga, CA, UNITED STATES  
Gallop, Mark A., Los Altos, CA, UNITED STATES  
PI US 2004254246 A1 20041216  
AI US 2004-816551 A1 20040331 (10)  
PRAI US 2003-459472P 20030331 (60)  
US 2003-512280P 20031017 (60)  
US 2004-538724P 20040122 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2597  
INCL INCLM: 514/561.000  
NCL NCLM: 514/561.000  
IC [7]  
ICM A61K031-195  
IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]  
IPCR A61K0031-185 [I,C\*]; A61K0031-195 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 77 USPATFULL on STN

Full Text

AN 2004:255290 USPATFULL  
TI Orally administered dosage forms of gaba analog prodrugs having reduced toxicity  
IN Cundy, Kenneth C., Redwood City, CA, UNITED STATES  
Gallop, Mark A., Los Altos, CA, UNITED STATES  
PI US 2004198820 A1 20041007  
AI US 2004-829896 A1 20040421 (10)  
RLI Continuation of Ser. No. US 2002-170127, filed on 11 Jun 2002, PENDING  
PRAI US 2001-297521P 20010611 (60)  
US 2001-298514P 20010614 (60)  
US 2002-366090P 20020319 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2469  
INCL INCLM: 514/557.000  
INCLS: 514/666.000  
NCL NCLM: 514/557.000  
NCLS: 514/666.000  
IC [7]  
ICM A61K031-19  
ICS A61K031-13  
IPCI A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-13 [ICS,7]  
IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-26 [I,C\*];

A61K0009-26 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19 [I,A];  
 C07C0271-00 [I,C\*]; C07C0271-22 [I,A]; C07C0323-00 [I,C\*];  
 C07C0323-58 [I,A]; C07D0213-00 [I,C\*]; C07D0213-80 [I,A];  
 C07D0267-00 [I,C\*]; C07D0267-06 [I,A]; C07D0307-00 [I,C\*];  
 C07D0307-58 [I,A]; C07D0317-00 [I,C\*]; C07D0317-32 [I,A];  
 C07D0317-40 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 77 USPATFULL on STN

Full Text

AN 2004:239300 USPATFULL  
 TI Gastric retentive oral dosage form with restricted drug release in the  
 lower gastrointestinal tract  
 IN Berner, Bret, El Granada, CA, UNITED STATES  
 Louie-Helm, Jenny, Union City, CA, UNITED STATES  
 PI US 2004185105 A1 20040923  
 AI US 2004-769574 A1 20040129 (10)  
 RLI Division of Ser. No. US 2001-24932, filed on 18 Dec 2001, PENDING  
 Continuation-in-part of Ser. No. US 2001-45816, filed on 25 Oct 2001,  
 ABANDONED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2022  
 INCL INCLM: 424/486.000  
 NCL NCLM: 424/486.000  
 IC [7]  
 ICM A61K009-14  
 IPCI A61K0009-14 [ICM,7]  
 IPCR A61K0047-34 [I,C\*]; A61K0047-34 [I,A]; A61K0009-00 [I,C\*];  
 A61K0009-00 [I,A]; A61K0009-127 [I,C\*]; A61K0009-127 [I,A];  
 A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*];  
 A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
 A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0009-51 [I,C\*];  
 A61K0009-51 [I,A]; A61K0031-00 [I,C\*]; A61K0031-00 [I,A];  
 A61K0031-165 [I,C\*]; A61K0031-165 [I,A]; A61K0031-185 [I,C\*];  
 A61K0031-195 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28 [I,A];  
 A61K0031-341 [I,C\*]; A61K0031-341 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4164 [I,A]; A61K0031-4196 [I,C\*]; A61K0031-4196 [I,A];  
 A61K0031-426 [I,C\*]; A61K0031-426 [I,A]; A61K0031-429 [I,C\*];  
 A61K0031-43 [I,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
 A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A]; A61K0031-58 [I,C\*];  
 A61K0031-58 [I,A]; A61K0031-65 [I,C\*]; A61K0031-65 [I,A];  
 A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]; A61K0047-32 [I,C\*];  
 A61K0047-32 [I,A]; A61K0047-36 [I,C\*]; A61K0047-36 [I,A];  
 A61K0047-38 [I,C\*]; A61K0047-38 [I,A]; A61P0001-00 [I,C\*];  
 A61P0001-04 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A];  
 A61P0031-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 77 USPATFULL on STN

Full Text

AN 2004:239291 USPATFULL  
 TI Melt-extrusion multiparticulates  
 IN Oshlack, Benjamin, New York, NY, UNITED STATES  
 Chasin, Mark, Manalapan, NJ, UNITED STATES  
 Huang, Hua-Pin, Englewood Cliffs, NJ, UNITED STATES  
 PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
 PI US 2004185096 A1 20040923  
 AI US 2003-745950 A1 20031223 (10)  
 RLI Continuation of Ser. No. US 2002-38867, filed on 2 Jan 2002, GRANTED,  
 Pat. No. US 6706281 Continuation of Ser. No. US 1999-358828, filed on 22  
 Jul 1999, GRANTED, Pat. No. US 6335033 Continuation of Ser. No. US  
 1994-334209, filed on 4 Nov 1994, GRANTED, Pat. No. US 5965161  
 DT Utility  
 FS APPLICATION  
 LN.CNT 854  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]  
 IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];

A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 77 USPATFULL on STN

Full Text

AN 2004:209917 USPATFULL  
TI Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity  
IN Gallop, Mark A., Los Altos, CA, UNITED STATES  
PI US 2004162351 A1 20040819  
AI US 2003-734631 A1 20031211 (10)  
PRAI US 2002-432931P 20021211 (60)  
US 2002-433243P 20021212 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2084  
INCL INCLM: 514/561.000  
NCL NCLM: 514/561.000  
IC [7]  
ICM A61K031-195  
IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]  
IPCR A61K0047-48 [I,C\*]; A61K0047-48 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 77 USPATFULL on STN

Full Text

AN 2004:203010 USPATFULL  
TI Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data  
IN Louie-Helm, Jenny, Union City, CA, UNITED STATES  
Bernier, Bret, El Granada, CA, UNITED STATES  
PI US 2004156899 A1 20040812  
AI US 2004-773986 A1 20040205 (10)  
RLI Division of Ser. No. US 2001-14750, filed on 25 Oct 2001, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 1847  
INCL INCLM: 424/468.000  
NCL NCLM: 424/468.000  
IC [7]  
ICM A61K009-22  
IPCI A61K0009-22 [ICM,7]  
IPCR A61K0047-32 [I,C\*]; A61K0047-32 [I,A]; A61K0009-00 [I,C\*];  
A61K0009-00 [I,A]; A61K0009-127 [I,C\*]; A61K0009-127 [I,A];  
A61K0009-20 [N,C\*]; A61K0009-20 [N,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-50 [N,C\*]; A61K0009-50 [N,A];  
A61K0009-51 [I,C\*]; A61K0009-51 [I,A]; A61K0031-155 [I,C\*];  
A61K0031-155 [I,A]; A61K0031-337 [I,C\*]; A61K0031-337 [I,A];  
A61K0031-341 [I,C\*]; A61K0031-341 [I,A]; A61K0031-35 [I,C\*];  
A61K0031-35 [I,A]; A61K0031-351 [I,C\*]; A61K0031-351 [I,A];  
A61K0031-357 [I,C\*]; A61K0031-36 [I,A]; A61K0031-496 [I,C\*];  
A61K0031-496 [I,A]; A61K0031-60 [I,C\*]; A61K0031-616 [I,A];  
A61K0031-63 [I,C\*]; A61K0031-635 [I,A]; A61K0033-00 [I,C\*];  
A61K0033-00 [I,A]; A61K0047-34 [I,C\*]; A61K0047-34 [I,A];  
A61K0047-36 [I,C\*]; A61K0047-36 [I,A]; A61K0047-38 [I,C\*];  
A61K0047-38 [I,A]; A61K0049-04 [I,C\*]; A61K0049-04 [I,A];  
A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*];  
A61P0003-10 [I,A]; A61P0007-00 [I,C\*]; A61P0007-10 [I,A];  
A61P0013-00 [I,C\*]; A61P0013-02 [I,A]; A61P0025-00 [I,C\*];  
A61P0025-08 [I,A]; A61P0033-00 [I,C\*]; A61P0033-04 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 77 USPATFULL on STN

Full Text

AN 2004:151041 USPATFULL  
TI Formulations and dosage forms for controlled delivery of topiramate  
IN Jao, Frank, San Jose, CA, UNITED STATES  
Edgren, David, Los Altos, CA, UNITED STATES  
Wong, Patrick S.L., Burlingame, CA, UNITED STATES  
Skluzacek, Robert, Newark, CA, UNITED STATES  
Li, Shu, Union City, CA, UNITED STATES

Lam, Andrew, South San Francisco, CA, UNITED STATES  
 Ayer, Atul, Palo Alto, CA, UNITED STATES  
 Li, Shaoling, Sunnyvale, CA, UNITED STATES  
 To, Winnie, Sunnyvale, CA, UNITED STATES  
 PI US 2004115262 A1 20040617  
 AI US 2003-628970 A1 20030728 (10)  
 PRAI US 2002-399993P 20020729 (60)  
 US 2003-468519P 20030507 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2429  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0031-35 [I,C\*]; A61K0031-35 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 77 USPATFULL on STN

Full Text

AN 2004:120123 USPATFULL  
 TI Methods and dosage forms for increasing solubility of drug compositions  
 for controlled delivery  
 IN Edgren, David, Los Altos, CA, UNITED STATES  
 Wong, Patrick S.L., Burlingame, CA, UNITED STATES  
 Jao, Frank, San Jose, CA, UNITED STATES  
 Skluzacek, Robert, Newark, CA, UNITED STATES  
 Li, Shu, Union City, CA, UNITED STATES  
 Lam, Andrew, South San Francisco, CA, UNITED STATES  
 Bhatti, Gurdish, Fremont, CA, UNITED STATES  
 Li, Shaoling, Sunnyvale, CA, UNITED STATES  
 Ayer, Atul, Palo Alto, CA, UNITED STATES  
 To, Winnie, Santa Clara, CA, UNITED STATES  
 PI US 2004091529 A1 20040513  
 AI US 2003-606575 A1 20030626 (10)  
 PRAI US 2002-392128P 20020626 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2171  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0031-35 [I,C\*]; A61K0031-35 [I,A];  
 A61K0031-4164 [I,C\*]; A61K0031-4166 [I,A]; A61K0047-34 [I,C\*];  
 A61K0047-34 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 77 USPATFULL on STN

Full Text

AN 2004:100806 USPATFULL  
 TI Sustained release pharmaceutical composition containing metformin  
 hydrochloride  
 IN Kumar Gidwani, Suresh, Govandi, INDIA  
 Singnurkar, Purushottam, Govandi, INDIA  
 Tewari, Prashant Kumar, Govandi, INDIA  
 PI US 2004076667 A1 20040422  
 AI US 2002-272812 A1 20021017 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 454  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]  
 IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
 A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];

A61K0031-155 [I,C\*]; A61K0031-155 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 77 USPATFULL on STN

Full Text

AN 2004:57071 USPATFULL  
TI Pharmaceutical compositions for drugs having pH-dependent solubility  
IN Chen, Chih-Ming, Taipei, TAIWAN, PROVINCE OF CHINA  
Li, Boyong, Morgantown, WV, UNITED STATES  
Nangia, Avinash, Weston, FL, UNITED STATES  
PI US 2004043073 A1 20040304  
AI US 2003-462581 A1 20030616 (10)  
PRAI US 2002-388704P 20020614 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1500  
INCL INCLM: 424/486.000  
INCLS: 514/029.000  
NCL NCLM: 424/486.000  
NCLS: 514/029.000  
IC [7]  
ICM A61K031-7048  
ICS A61K009-14  
IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C\*]; A61K0009-14  
[ICS,7]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-28 [N,C\*];  
A61K0009-28 [N,A]; A61K0031-70 [I,C\*]; A61K0031-70 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 77 USPATFULL on STN

Full Text

AN 2003:324386 USPATFULL  
TI Sustained release metoprolol formulations  
IN Baichwal, Anand R., Wappingers Fall, NY, UNITED STATES  
Woodcock, Paul, Brookfield, CT, UNITED STATES  
Sanghvi, Pradeepkumar P., New Fairfield, CT, UNITED STATES  
Dinicola, Dean M., Prospect, CT, UNITED STATES  
McCall, Troy W., Germantown, TN, UNITED STATES  
PI US 2003228361 A1 20031211  
AI US 2003-408739 A1 20030407 (10)  
PRAI US 2002-370460P 20020405 (60)  
US 2003-442228P 20030124 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2456  
INCL INCLM: 424/468.000  
INCLS: 514/651.000  
NCL NCLM: 424/468.000  
NCLS: 514/651.000  
IC [7]  
ICM A61K009-22  
ICS A61K031-137  
IPCI A61K0009-22 [ICM,7]; A61K0031-137 [ICS,7]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A];  
A61K0031-138 [I,C\*]; A61K0031-138 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 77 USPATFULL on STN

Full Text

AN 2003:318309 USPATFULL  
TI Dosage forms and compositions for osmotic delivery of variable dosages  
of oxycodone  
IN Fink, Tracy A., Campbell, CA, UNITED STATES  
Ayer, Atul D., Palo Alto, CA, UNITED STATES  
Johnson, Deborah J., Palo Alto, CA, UNITED STATES  
Shivanand, Padmaja, Mountain View, CA, UNITED STATES  
Allphin, Clark P., Mountain View, CA, UNITED STATES  
PI US 2003224051 A1 20031204  
AI US 2003-447910 A1 20030528 (10)  
PRAI US 2002-384442P 20020531 (60)  
DT Utility



FS APPLICATION  
LN.CNT 2133  
INCL INCLM: 424/473.000  
INCLS: 514/282.000  
NCL NCLM: 424/473.000  
NCLS: 514/282.000  
IC [7]  
ICM A61K031-485  
ICS A61K009-24  
IPCI A61K0031-485 [ICM,7]; A61K0009-24 [ICS,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 77 USPATFULL on STN

Full Text

AN 2003:311886 USPATFULL  
TI Novel once-a-day controlled release sulfonylurea formulation  
IN Bhagwat, Dileep, Bronxville, NY, UNITED STATES  
Diehl, Donald, II, Stony Point, NY, UNITED STATES  
Baichwal, Anand R., Wappinger Falls, NY, UNITED STATES  
PI US 2003219481 A1 20031127  
US 6875793 B2 20050405  
AI US 2003-396114 A1 20030325 (10)  
RLI Continuation of Ser. No. US 2000-479465, filed on 7 Jan 2000, GRANTED,  
Pat. No. US 6537578 Continuation of Ser. No. US 1997-950732, filed on 15  
Oct 1997, GRANTED, Pat. No. US 6056977  
DT Utility  
FS APPLICATION  
LN.CNT 1344  
INCL INCLM: 424/468.000  
INCLS: 514/369.000; 514/054.000  
NCL NCLM: 514/593.000; 424/468.000  
NCLS: 514/255.060; 514/866.000; 514/054.000; 514/369.000  
IC [7]  
ICM A61K031-426  
ICS A61K009-22  
IPCI A61K0031-426 [ICM,7]; A61K0009-22 [ICS,7]  
IPCI-2 A61K0031-4965 [ICM,7]; A61K0031-64 [ICS,7]; A61P0005-30 [ICS,7];  
A61P0005-00 [ICS,7,C\*]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-28 [N,C\*]; A61K0009-28 [N,A];  
A61K0031-64 [I,C\*]; A61K0031-64 [I,A]; A61P0005-00 [I,C\*];  
A61P0005-30 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 77 USPATFULL on STN

Full Text

AN 2003:258337 USPATFULL  
TI Amino acid conjugates providing for sustained systemic concentrations of  
GABA analogues  
IN Gallop, Mark A., Los Altos, CA, UNITED STATES  
Cundy, Kenneth C., Redwood City, CA, UNITED STATES  
Scheuerman, Randall A., Santa Clara, CA, UNITED STATES  
Barrett, Ronald W., Saratoga, CA, UNITED STATES  
PI US 2003181390 A1 20030925  
AI US 2002-167381 A1 20020612 (10)  
PRAI US 2002-364619P 20020318 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4007  
INCL INCLM: 514/019.000  
NCL NCLM: 514/019.000  
IC [7]  
ICM A61K038-00  
IPCI A61K0038-00 [ICM,7]  
IPCR A61K0038-00 [N,C\*]; A61K0038-00 [N,A]; A61K0047-48 [I,C\*];  
A61K0047-48 [I,A]; C07C0237-00 [I,C\*]; C07C0237-12 [I,A];  
C07C0237-20 [I,A]; C07C0317-00 [I,C\*]; C07C0317-50 [I,A];  
C07C0323-00 [I,C\*]; C07C0323-59 [I,A]; C07C0323-60 [I,A];  
C07D0207-00 [I,C\*]; C07D0207-16 [I,A]; C07D0233-00 [I,C\*];  
C07D0233-54 [I,A]; C07K0005-00 [I,C\*]; C07K0005-02 [I,A];

G01N0033-566 [I,C\*]; G01N0033-566 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 77 USPATFULL on STN

Full Text

AN 2003:225358 USPATFULL  
TI Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride  
IN Sauer, Joseph Peter, Sarasota, FL, UNITED STATES  
Milosovich, Susan Marie, Phoenixville, PA, UNITED STATES  
Muldoon, William Thomas, Philadelphia, PA, UNITED STATES  
Napper, James Albert, Pound Hill, UNITED KINGDOM  
Rousseau, Laurence, Broxbourne, UNITED KINGDOM  
PA SmithKline Beecham Corporation and SmithKline Beecham p.l.c. (U.S. corporation)  
PI US 2003157169 A1 20030821  
AI US 2002-229645 A1 20020828 (10)  
RLI Continuation of Ser. No. US 2001-956617, filed on 19 Sep 2001, GRANTED, Pat. No. US 6468560 Continuation of Ser. No. US 2001-759576, filed on 12 Jan 2001, ABANDONED Continuation of Ser. No. US 1999-254621, filed on 11 Mar 1999, ABANDONED A 371 of International Ser. No. WO 1997-GB2418, filed on 8 Sep 1997, UNKNOWN  
PRAI GB 1996-19074 19960912  
DT Utility  
FS APPLICATION  
LN.CNT 915  
INCL INCLM: 424/468.000  
INCLS: 514/304.000  
NCL NCLM: 424/468.000  
NCLS: 514/304.000  
IC [7]  
ICM A61K009-22  
IPCI A61K0009-22 [ICM,7]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-50 [I,C\*]; A61K0009-50 [I,A]; A61K0031-439 [I,C\*]; A61K0031-439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 77 USPATFULL on STN

Full Text

AN 2003:225355 USPATFULL  
TI Controlled release sulfonylurea formulation  
IN Chen, Chih Ming, Davie, FL, UNITED STATES  
Chou, Joseph, Manassas, VA, UNITED STATES  
Wong, David, Milpitas, CA, UNITED STATES  
PI US 2003157166 A1 20030821  
AI US 2002-101438 A1 20020318 (10)  
PRAI US 2001-276447P 20010316 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1436  
INCL INCLM: 424/468.000  
INCLS: 514/369.000  
NCL NCLM: 424/468.000  
NCLS: 514/369.000  
IC [7]  
ICM A61K009-22  
ICS A61K031-426  
IPCI A61K0009-22 [ICM,7]; A61K0031-426 [ICS,7]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 77 USPATFULL on STN

Full Text

AN 2003:219332 USPATFULL  
TI Formulation of an erodible, gastric retentive oral diuretic  
IN Louie-Helm, Jenny, Union City, CA, UNITED STATES  
Bernier, Bret, El Granada, CA, UNITED STATES  
Urquhart, John, Palo Alto, CA, UNITED STATES  
PI US 2003152622 A1 20030814

AI US 2002-293217 A1 20021112 (10)  
 RLI Continuation-in-part of Ser. No. US 2002-281284, filed on 25 Oct 2002,  
 PENDING Continuation-in-part of Ser. No. US 2001-14750, filed on 25 Oct  
 2001, PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2108  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-14  
 IPCI A61K0009-22 [ICM,7]; A61K0009-14 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-20 [N,C\*];  
 A61K0009-20 [N,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
 A61K0009-50 [N,C\*]; A61K0009-50 [N,A]; A61K0031-35 [I,C\*];  
 A61K0031-35 [I,A]; A61K0031-351 [I,C\*]; A61K0031-351 [I,A];  
 A61K0031-63 [I,C\*]; A61K0031-635 [I,A]; A61K0033-00 [I,C\*];  
 A61K0033-00 [I,A]; A61K0049-04 [I,C\*]; A61K0049-04 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 77 USPATFULL on STN

Full Text

AN 2003:194175 USPATFULL  
 TI Formulation of an erodible, gastric retentive oral dosage form using in  
 vitro disintegration test data  
 IN Louie-Helm, Jenny, Union City, CA, UNITED STATES  
 Berner, Bret, El Granada, CA, UNITED STATES  
 PI US 2003133985 A1 20030717  
 AI US 2002-281284 A1 20021025 (10)  
 RLI Continuation-in-part of Ser. No. US 2001-14750, filed on 25 Oct 2001,  
 PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2205  
 INCL INCLM: 424/486.000  
 INCLS: 424/488.000; 514/217.000; 514/449.000; 514/255.040; 514/471.000;  
 514/252.170; 514/464.000; 514/355.000; 514/389.000  
 NCL NCLM: 424/486.000  
 NCLS: 424/488.000; 514/217.000; 514/252.170; 514/255.040; 514/355.000;  
 514/389.000; 514/449.000; 514/464.000; 514/471.000  
 IC [7]  
 ICM A61K031-55  
 ICS A61K031-495; A61K031-337; A61K031-343; A61K031-455; A61K031-4162  
 IPCI A61K0031-55 [ICM,7]; A61K0031-495 [ICS,7]; A61K0031-337 [ICS,7];  
 A61K0031-343 [ICS,7]; A61K0031-455 [ICS,7]; A61K0031-4162 [ICS,7]  
 IPCR A61K0047-32 [I,C\*]; A61K0047-32 [I,A]; A61K0009-00 [I,C\*];  
 A61K0009-00 [I,A]; A61K0009-127 [I,C\*]; A61K0009-127 [I,A];  
 A61K0009-20 [N,C\*]; A61K0009-20 [N,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-50 [N,C\*]; A61K0009-50 [N,A];  
 A61K0009-51 [I,C\*]; A61K0009-51 [I,A]; A61K0031-155 [I,C\*];  
 A61K0031-155 [I,A]; A61K0031-337 [I,C\*]; A61K0031-337 [I,A];  
 A61K0031-341 [I,C\*]; A61K0031-341 [I,A]; A61K0031-35 [I,C\*];  
 A61K0031-35 [I,A]; A61K0031-351 [I,C\*]; A61K0031-351 [I,A];  
 A61K0031-357 [I,C\*]; A61K0031-36 [I,A]; A61K0031-496 [I,C\*];  
 A61K0031-496 [I,A]; A61K0031-60 [I,C\*]; A61K0031-616 [I,A];  
 A61K0031-63 [I,C\*]; A61K0031-635 [I,A]; A61K0033-00 [I,C\*];  
 A61K0033-00 [I,A]; A61K0047-34 [I,C\*]; A61K0047-34 [I,A];  
 A61K0047-36 [I,C\*]; A61K0047-36 [I,A]; A61K0047-38 [I,C\*];  
 A61K0047-38 [I,A]; A61K0049-04 [I,C\*]; A61K0049-04 [I,A];  
 A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*];  
 A61P0003-10 [I,A]; A61P0007-00 [I,C\*]; A61P0007-10 [I,A];  
 A61P0013-00 [I,C\*]; A61P0013-02 [I,A]; A61P0025-00 [I,C\*];  
 A61P0025-08 [I,A]; A61P0033-00 [I,C\*]; A61P0033-04 [I,A];  
 A61P0035-00 [I,C\*]; A61P0035-00 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 77 USPATFULL on STN

Full Text

AN 2003:152386 USPATFULL  
 TI Gastric retentive oral dosage form with restricted drug release in the  
 lower gastrointestinal tract

IN Berner, Bret, El Granada, CA, UNITED STATES  
 Louie-Helm, Jenny, Union City, CA, UNITED STATES  
 PI US 2003104052 A1 20030605  
 AI US 2001-24932 A1 20011218 (10)  
 RLI Continuation-in-part of Ser. No. US 2001-45816, filed on 25 Oct 2001,  
 PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2156  
 INCL INCLM: 424/468.000  
 NCL NCLM: 424/468.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-14  
 IPCI A61K0009-22 [ICM,7]; A61K0009-14 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-20 [N,C\*];  
 A61K0009-20 [N,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
 A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-65 [I,C\*];  
 A61K0031-65 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 77 USPATFULL on STN

Full Text

AN 2003:120898 USPATFULL  
 TI Orally administered dosage forms of GABA analog prodrugs having reduced  
 toxicity  
 IN Cundy, Kenneth C., Redwood City, CA, UNITED STATES  
 Gallop, Mark A., Los Altos, CA, UNITED STATES  
 PI US 2003083382 A1 20030501  
 US 6833140 B2 20041221  
 AI US 2002-170127 A1 20020611 (10)  
 PRAI US 2001-297521P 20010611 (60)  
 US 2001-298514P 20010614 (60)  
 US 2002-366090P 20020319 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2468  
 INCL INCLM: 514/561.000  
 INCLS: 514/563.000  
 NCL NCLM: 424/468.000; 514/561.000  
 NCLS: 424/464.000; 424/465.000; 514/533.000; 514/547.000; 514/561.000;  
 514/563.000  
 IC [7]  
 ICM A61K031-195  
 IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C\*]  
 IPCI-2 A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-26 [ICS,7];  
 A01N0037-02 [ICS,7]; A01N0037-10 [ICS,7]  
 IPCR A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-26 [I,C\*];  
 A61K0009-26 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19 [I,A];  
 C07C0271-00 [I,C\*]; C07C0271-22 [I,A]; C07C0323-00 [I,C\*];  
 C07C0323-58 [I,A]; C07D0213-00 [I,C\*]; C07D0213-80 [I,A];  
 C07D0267-00 [I,C\*]; C07D0267-06 [I,A]; C07D0307-00 [I,C\*];  
 C07D0307-58 [I,A]; C07D0317-00 [I,C\*]; C07D0317-32 [I,A];  
 C07D0317-40 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 77 USPATFULL on STN

Full Text

AN 2003:40433 USPATFULL  
 TI Sertraline salts and sustained-release dosage forms of sertraline  
 IN Am Ende, Mary Tanya, Griswold, CT, United States  
 Curatolo, William John, Niantic, CT, United States  
 Friedman, Hylar Lewis, Brattleboro, VT, United States  
 Friesen, Dwayne Thomas, Bend, OR, United States  
 Herbig, Scott Max, East Lyme, CT, United States  
 Shankar, Ravi Mysore, Groton, CT, United States  
 West, James Blair, Bend, OR, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6517866 B1 20030211  
 WO 9901121 19990114  
 AI US 1999-380897 19990907 (9)  
 WO 1998-IB934 19980615

PRAI US 1997-51498P 19970701 (60)  
 US 1997-51420P 19970701 (60)  
 US 1997-51414P 19970701 (60)  
 US 1997-51402P 19970701 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 5178  
 INCL INCLM: 424/457.000  
 INCLS: 424/458.000; 424/468.000; 424/469.000; 424/473.000; 424/474.000;  
 424/484.000; 424/490.000; 424/463.000  
 NCL NCLM: 424/457.000  
 NCLS: 424/458.000; 424/463.000; 424/468.000; 424/469.000; 424/473.000;  
 424/474.000; 424/484.000; 424/490.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K009-26; A61K009-44; A61K009-52; A61K009-54  
 IPCI A61K0009-22 [ICM,7]; A61K0009-26 [ICS,7]; A61K0009-44 [ICS,7];  
 A61K0009-52 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C\*]  
 IPCR A61K0009-00 [N,C\*]; A61K0009-00 [N,A]; A61K0009-16 [N,C\*];  
 A61K0009-16 [N,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-26 [I,C\*];  
 A61K0009-26 [I,A]; A61K0009-28 [N,C\*]; A61K0009-28 [N,A];  
 A61K0009-50 [N,C\*]; A61K0009-50 [N,A]; A61K0009-52 [I,C\*];  
 A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0031-135 [I,C\*];  
 A61K0031-135 [I,A]  
 EXP 424/451; 424/464; 424/456; 424/465; 424/468; 424/469; 424/472; 424/474;  
 424/475; 424/489; 424/463; 424/457; 424/484; 424/490; 424/473; 424/458  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 50 OF 77 USPATFULL on STN

Full Text

AN 2003:37195 USPATFULL  
 TI Melt-extrusion multiparticulates  
 IN Oshlack, Benjamin, New York, NY, UNITED STATES  
 Chasin, Mark, Manalapan, NJ, UNITED STATES  
 Huang, Hua-Pin, Englewood Cliffs, NJ, UNITED STATES  
 PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (U.S. corporation)  
 PI US 2003026839 A1 20030206  
 US 6706281 B2 20040316  
 AI US 2002-38867 A1 20020102 (10)  
 RLI Continuation of Ser. No. US 1999-358828, filed on 22 Jul 1999, GRANTED,  
 Pat. No. US 6335033 Continuation of Ser. No. US 1994-334209, filed on 4  
 Nov 1994, GRANTED, Pat. No. US 5965161  
 DT Utility  
 FS APPLICATION  
 LN.CNT 852  
 INCL INCLM: 424/469.000  
 INCLS: 514/282.000; 504/367.000; 424/417.000  
 NCL NCLM: 424/457.000; 424/469.000  
 NCLS: 424/451.000; 424/452.000; 424/456.000; 424/489.000; 514/772.300;  
 514/772.600; 514/781.000; 514/783.000; 514/784.000; 514/785.000;  
 514/786.000; 514/951.000; 514/962.000; 424/417.000; 504/367.000;  
 514/282.000  
 IC [7]  
 ICM A01N025-12  
 ICS A01N043-42; A01N025-26; A61K009-52; A61K031-485  
 IPCI A01N0025-12 [ICM,7]; A01N0043-42 [ICS,7]; A01N0043-34 [ICS,7,C\*];  
 A01N0025-26 [ICS,7]; A61K0009-52 [ICS,7]; A61K0031-485 [ICS,7]  
 IPCI-2 A61K0009-16 [ICM,7]; A61K0009-52 [ICS,7]  
 IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
 A61K0009-20 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 77 USPATFULL on STN

Full Text

AN 2002:238668 USPATFULL  
 TI Composition for treating dementia and Alzheimer's disease  
 IN Glinecke, Robert, Pottstown, PA, United States  
 Muldoon, William, Philadelphia, PA, United States  
 Milosovich, Susan Marie, West Chester, PA, United States  
 Sauer, Joseph, Sarasota, FL, United States  
 Rousseau, Laurence, Broxbourne, UNITED KINGDOM

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)  
SmithKline Beecham p.l.c., Brentford, UNITED KINGDOM (non-U.S. corporation)

PI US 6451343 B1 20020917  
WO 9945924 19990916

AI US 2000-623213 20000830 (9)  
WO 1999-EP1557 19990305  
20000830 PCT 371 date

PRAI GB 1998-5192 19980311  
US 1998-77527P 19980311 (60)  
US 1998-77480P 19980311 (60)

DT Utility  
FS GRANTED  
LN.CNT 589

INCL INCLM: 424/478.000  
INCLS: 424/464.000; 424/465.000; 424/468.000; 424/474.000; 424/475.000;  
424/470.000

NCL NCLM: 424/478.000  
NCLS: 424/464.000; 424/465.000; 424/468.000; 424/470.000; 424/474.000;  
424/475.000

IC [7]  
ICM A61K009-40  
ICS A61K009-30; A61K009-28; A61K009-22; A61K009-20  
IPCI A61K0009-40 [ICM,7]; A61K0009-30 [ICS,7]; A61K0009-28 [ICS,7];  
A61K0009-22 [ICS,7]; A61K0009-20 [ICS,7]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A];  
A61K0009-30 [I,C\*]; A61K0009-30 [I,A]; A61K0009-40 [I,A];  
A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0031-439 [I,C\*];  
A61K0031-439 [I,A]

EXF 424/451; 424/464; 424/465; 424/468; 424/469; 424/470  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 77 USPATFULL on STN

Full Text

AN 2002:140882 USPATFULL  
TI Antiviral medication  
IN Dong, Liang C., Sunnyvale, CA, UNITED STATES  
Espinal, Steven D., Mountain View, CA, UNITED STATES  
Wong, Patrick S.-L., Burlingame, CA, UNITED STATES  
Magruder, Paul R., Mountain View, CA, UNITED STATES

PI US 2002071863 A1 20020613  
AI US 2000-733847 A1 20001208 (9)  
PRAI US 1999-169883P 19991209 (60)

DT Utility  
FS APPLICATION  
LN.CNT 1276

INCL INCLM: 424/455.000  
NCL NCLM: 424/455.000  
IC [7]  
ICM A61K009-66  
ICS A61K009-24  
IPCI A61K0009-66 [ICM,7]; A61K0009-52 [ICM,7,C\*]; A61K0009-24 [ICS,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-52 [I,C\*];  
A61K0009-52 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 53 OF 77 USPATFULL on STN

Full Text

AN 2002:54391 USPATFULL  
TI Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl) acetonitrile monohydrochloride  
IN Sauer, Joseph Peter, Sarasota, FL, UNITED STATES  
Milosovich, Susan Marie, Phoenixville, PA, UNITED STATES  
Muldoon, William Thomas, Philadelphia, PA, UNITED STATES  
Napper, James Albert, Pound Hill, UNITED KINGDOM  
Rousseau, Laurence, Broxbourne, UNITED KINGDOM

PA SmithKline Beecham Corporation and SmithKline Beecham p.l.c.  
PI US 2002031550 A1 20020314  
US 6468560 B2 20021022  
AI US 2001-956617 A1 20010919 (9)

RLI Continuation of Ser. No. US 2001-759576, filed on 12 Jan 2001, ABANDONED  
Continuation of Ser. No. US 1999-254621, filed on 11 Mar 1999, ABANDONED  
A 371 of International Ser. No. WO 1997-GB2418, filed on 8 Sep 1997,  
UNKNOWN

PRAI GB 1996-19074 19960912

DT Utility

FS APPLICATION

LN.CNT 885

INCL INCLM: 424/468.000  
INCLS: 424/469.000

NCL NCLM: 424/451.000; 424/468.000  
NCLS: 424/463.000; 424/464.000; 424/468.000; 424/472.000; 424/489.000;  
424/490.000; 424/469.000

IC [7]  
ICM A61K009-22  
ICS A61K009-26  
IPCI A61K0009-22 [ICM,7]; A61K0009-26 [ICS,7]  
IPCI-2 A61K0009-48 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7];  
A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
A61K0009-26 [I,C\*]; A61K0009-26 [I,A]; A61K0009-50 [I,C\*];  
A61K0009-50 [I,A]; A61K0031-439 [I,C\*]; A61K0031-439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 77 USPATFULL on STN

Full Text

AN 2001:188235 USPATFULL

TI MELT-EXTRUSION MULTIPARTICULATES

IN OSHLACK, BENJAMIN, NEW YORK, NY, United States  
HUANG, HUA-PIN, ENGLEWOOD CLIFFS, NJ, United States  
CHASIN, MARK, MANALAPAN, NJ, United States

PI US 2001033865 A1 20011025  
US 6335033 B2 20020101

AI US 1999-358828 A1 19990722 (9)

RLI Continuation of Ser. No. US 1994-334209, filed on 4 Nov 1994, GRANTED,  
Pat. No. US 5965161

DT Utility

FS APPLICATION

LN.CNT 854

INCL INCLM: 424/457.000  
NCL NCLM: 424/457.000  
NCLS: 424/451.000; 424/452.000; 424/456.000; 424/487.000; 424/488.000;  
424/489.000; 514/772.600; 514/781.000; 514/784.000; 514/785.000;  
514/786.000; 514/951.000; 514/962.000

IC [7]  
ICM A61K009-52  
IPCI A61K0009-52 [ICM,7]  
IPCI-2 A61K0009-16 [ICM,7]; A61K0009-52 [ICS,7]  
IPCR A61K0009-14 [N,C\*]; A61K0009-14 [N,A]; A61K0009-16 [I,C\*];  
A61K0009-16 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-52 [I,C\*];  
A61K0009-52 [I,A]; A61K0031-135 [I,C\*]; A61K0031-135 [I,A];  
A61K0031-485 [I,C\*]; A61K0031-485 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 55 OF 77 USPATFULL on STN

Full Text

AN 2001:91439 USPATFULL

TI Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride

IN Sauer, Joseph Peter, Sarasota, FL, United States  
Milosovich, Susan Marie, Phoenixville, PA, United States  
Muldoon, William Thomas, Philadelphia, PA, United States  
Napper, James Albert, Pound Hill, Great Britain  
Rousseau, Laurence, Broxbourne, Great Britain

PA SmithKline Beecham Corporation (U.S. corporation)

PI US 2001003588 A1 20010614

AI US 2001-759576 A1 20010112 (9)

RLI Continuation of Ser. No. US 1999-254621, filed on 11 Mar 1999, PENDING A  
371 of International Ser. No. WO 1997-GB2418, filed on 8 Sep 1997,  
UNKNOWN

PRAI GB 1996-19074 19960912  
 DT Utility  
 FS APPLICATION  
 LN.CNT 919  
 INCL INCLM: 424/451.000  
 INCLS: 424/489.000; 424/486.000; 424/487.000; 424/490.000; 424/497.000;  
 424/464.000; 424/472.000; 424/499.000; 424/502.000; 424/501.000;  
 424/494.000; 424/495.000  
 NCL NCLM: 424/451.000  
 NCLS: 424/464.000; 424/472.000; 424/486.000; 424/487.000; 424/489.000;  
 424/490.000; 424/494.000; 424/495.000; 424/497.000; 424/499.000;  
 424/501.000; 424/502.000  
 IC [7]  
 ICM A61K009-20  
 ICS A61K009-48; A61K009-24; A61K009-14; A61K009-16; A61K009-50  
 IPCI A61K0009-20 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-24 [ICS,7];  
 A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-50 [ICS,7]  
 IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-20 [I,C\*]; A61K0009-50 [I,A]; A61K0009-50 [I,C\*];  
 A61K0031-439 [I,A]; A61K0031-439 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 77 USPATFULL on STN

Full Text

AN 2001:86060 USPATFULL  
 TI Sustained release heterodisperse hydrogel systems-amorphous drugs  
 IN Baichwal, Anand, Wappingers Falls, NY, United States  
 PA Edward Mendell Co., Inc., Patterson, NY, United States (U.S. corporation)  
 PI US 6245356 B1 20010612  
 AI US 2000-498448 20000204 (9)  
 RLI Continuation of Ser. No. US 1998-106438, filed on 29 Jun 1998, now patented, Pat. No. US 6048548 Continuation of Ser. No. US 1996-634295, filed on 18 Apr 1996, now patented, Pat. No. US 5773025 Continuation-in-part of Ser. No. US 1995-447236, filed on 22 May 1995, now patented, Pat. No. US 5554387 Division of Ser. No. US 1993-118924, filed on 9 Sep 1993, now patented, Pat. No. US 5455046  
 DT Utility  
 FS GRANTED  
 LN.CNT 1618  
 INCL INCLM: 424/468.000  
 INCLS: 424/480.000; 424/481.000; 424/482.000  
 NCL NCLM: 424/468.000  
 NCLS: 424/480.000; 424/481.000; 424/482.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K047-30  
 IPCI A61K0009-22 [ICM,7]; A61K0047-30 [ICS,7]  
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C\*]; A61K0009-28 [I,A];  
 A61K0009-28 [I,C\*]; C08J0003-02 [I,C\*]; C08J0003-075 [I,A]  
 EXF 424/468  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 57 OF 77 USPATFULL on STN

Full Text

AN 2000:149743 USPATFULL  
 TI Method of treating humans with opioid formulations having extended controlled release  
 IN Sackler, Richard, Greenwich, CT, United States  
 Kaiko, Robert, Weston, CT, United States  
 Goldenheim, Paul, Wilton, CT, United States  
 PA Purdue Pharma L.P., Norwalk, CT, United States (U.S. corporation)  
 PI US 6143322 20001107  
 AI US 1997-838368 19970408 (8)  
 RLI Continuation of Ser. No. US 1996-677797, filed on 10 Jul 1996, now abandoned which is a continuation of Ser. No. US 1995-561829, filed on 27 Nov 1995, now patented, Pat. No. US 5958459 which is a continuation of Ser. No. US 1993-86248, filed on 1 Jul 1993, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1295  
 INCL INCLM: 424/459.000



INCLS: 424/458.000; 424/461.000; 424/462.000; 424/490.000; 424/495.000;  
424/497.000; 514/282.000  
NCL NCLM: 424/459.000  
NCLS: 424/458.000; 424/461.000; 424/462.000; 424/490.000; 424/495.000;  
424/497.000; 514/282.000  
IC [7]  
ICM A61K009-58  
ICS A61K009-60  
IPCI A61K0009-58 [ICM,7]; A61K0009-60 [ICS,7]; A61K0009-52 [ICS,7,C\*]  
IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C\*]; A61K0009-20 [I,A];  
A61K0009-20 [I,C\*]; A61K0009-28 [I,A]; A61K0009-28 [I,C\*];  
A61K0009-50 [I,A]; A61K0009-50 [I,C\*]; A61K0031-485 [I,A];  
A61K0031-485 [I,C\*]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A]  
EXF 424/458; 424/462; 424/459; 424/451; 424/480; 424/482; 424/461; 424/490;  
424/495; 424/497; 514/282; 514/289; 514/648  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 77 USPATFULL on STN

Full Text

AN 2000:105446 USPATFULL  
TI Opioid formulations having extended controlled release  
IN Chasin, Mark, Manalapan, NJ, United States  
Oshlack, Benjamin, New York, NY, United States  
Pedi, Jr., Frank, Yorktown Heights, NY, United States  
PA Purdue Pharma LP, Norwalk, CT, United States (U.S. corporation)  
PI US 6103261 20000815  
AI US 1999-225959 19990106 (9)  
RLI Continuation of Ser. No. US 1995-561829, filed on 27 Nov 1995, now  
patented, Pat. No. US 5958459 which is a continuation of Ser. No. US  
1993-86248, filed on 1 Jul 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1300  
INCL INCLM: 424/459.000  
INCLS: 424/451.000; 424/484.000; 424/486.000; 424/488.000; 424/495.000;  
424/497.000  
NCL NCLM: 424/459.000  
NCLS: 424/451.000; 424/484.000; 424/486.000; 424/488.000; 424/495.000;  
424/497.000  
IC [7]  
ICM A61K009-20  
ICS A61K009-28  
IPCI A61K0009-20 [ICM,7]; A61K0009-28 [ICS,7]  
IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C\*]; A61K0009-20 [I,A];  
A61K0009-20 [I,C\*]; A61K0009-28 [I,A]; A61K0009-28 [I,C\*];  
A61K0009-50 [I,A]; A61K0009-50 [I,C\*]; A61K0031-519 [I,C\*];  
A61K0031-522 [I,A]  
EXF 424/451; 424/457; 424/458; 424/459; 424/461; 424/462; 424/464; 424/468;  
424/469; 424/480; 424/482; 424/484; 424/487; 424/488; 424/486; 424/490;  
424/494; 424/495; 424/496; 424/497; 514/965  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 59 OF 77 USPATFULL on STN

Full Text

AN 2000:53761 USPATFULL  
TI Once-a-day controlled release sulfonylurea formulation  
IN Bhagwat, Dileep, Bronxville, NY, United States  
Diehl, II, Donald, Stony Point, NY, United States  
Baichwal, Anand R., Wappinger Falls, NY, United States  
PA Edward Mendell Co., Inc., Patterson, NY, United States (U.S.  
corporation)  
PI US 6056977 20000502  
AI US 1997-950732 19971015 (8)  
DT Utility  
FS Granted  
LN.CNT 1379  
INCL INCLM: 424/488.000  
INCLS: 424/468.000; 424/499.000; 424/500.000; 424/485.000; 424/458.000  
NCL NCLM: 424/488.000  
NCLS: 424/458.000; 424/468.000; 424/485.000; 424/499.000; 424/500.000  
IC [7]  
ICM A61K009-10

ICS A61K009-16; A61K009-22; A61K047-36  
 IPCI A61K0009-10 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-22 [ICS,7];  
 A61K0047-36 [ICS,7]  
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C\*]; A61K0009-28 [N,A];  
 A61K0009-28 [N,C\*]; A61K0031-64 [I,A]; A61K0031-64 [I,C\*]  
 EXF 424/484; 424/485; 424/488; 424/468-470; 424/457-458; 424/499; 424/500  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 60 OF 77 USPATFULL on STN

Full Text

AN 2000:43789 USPATFULL  
 TI Sustained release heterodisperse hydrogel systems-amorphous drugs  
 IN Baichwal, Anand, Wappingers Falls, NY, United States  
 PA Edward Mendell Co., Inc., Patterson, NY, United States (U.S.  
 corporation)  
 PI US 6048548 20000411  
 AI US 1998-106438 19980629 (9)  
 RLI Continuation of Ser. No. US 1996-634295, filed on 18 Apr 1996, now  
 patented, Pat. No. US 5773025 which is a continuation-in-part of Ser.  
 No. US 1995-447236, filed on 22 May 1995, now patented, Pat. No. US  
 5554387 which is a division of Ser. No. US 1993-118924, filed on 9 Sep  
 1993, now patented, Pat. No. US 5455046  
 DT Utility  
 FS Granted  
 LN.CNT 1692  
 INCL INCLM: 424/468.000  
 INCLS: 424/480.000; 424/481.000; 424/482.000  
 NCL NCLM: 424/468.000  
 NCLS: 424/480.000; 424/481.000; 424/482.000  
 IC [7]  
 ICM A61K009-22  
 ICS A61K047-30  
 IPCI A61K0009-22 [ICM,7]; A61K0047-30 [ICS,7]  
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C\*]; A61K0009-28 [I,A];  
 A61K0009-28 [I,C\*]; C08J0003-02 [I,C\*]; C08J0003-075 [I,A]  
 EXF 424/468; 424/469  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 61 OF 77 USPATFULL on STN

Full Text

AN 1999:124498 USPATFULL  
 TI Extruded multi-particulates  
 IN Oshlack, Benjamin, New York, NY, United States  
 Chasin, Mark, Manalapan, NJ, United States  
 Huang, Hua-Pin, Englewood Cliffs, NJ, United States  
 PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)  
 PI US 5965161 19991012  
 AI US 1994-334209 19941104 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1086  
 INCL INCLM: 424/457.000  
 INCLS: 424/456.000; 424/468.000; 424/484.000; 424/486.000; 424/487.000;  
 424/488.000; 424/489.000; 514/772.300; 514/772.600; 514/781.000;  
 514/783.000; 514/784.000  
 NCL NCLM: 424/457.000  
 NCLS: 424/456.000; 424/468.000; 424/484.000; 424/486.000; 424/487.000;  
 424/488.000; 424/489.000; 514/772.300; 514/772.600; 514/781.000;  
 514/783.000; 514/784.000  
 IC [6]  
 ICM A61K009-16  
 ICS A61K009-22; A61K009-26; A61K009-52  
 IPCI A61K0009-16 [ICM,6]; A61K0009-22 [ICS,6]; A61K0009-26 [ICS,6];  
 A61K0009-52 [ICS,6]  
 IPCR A61K0009-14 [N,C\*]; A61K0009-14 [N,A]; A61K0009-16 [I,C\*];  
 A61K0009-16 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-52 [I,C\*];  
 A61K0009-52 [I,A]; A61K0031-135 [I,C\*]; A61K0031-135 [I,A];  
 A61K0031-485 [I,C\*]; A61K0031-485 [I,A]  
 EXF 424/489; 424/451; 424/456; 424/457; 424/464; 424/468; 424/484; 424/486;  
 424/487; 424/488  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 62 OF 77 USPATFULL on STN

Full Text

AN 1999:117031 USPATFULL  
TI Opioid formulations having extended controlled released  
IN Chasin, Mark, Manalapan, NJ, United States  
Oshlack, Benjamin, New York, NY, United States  
Pedi, Jr., Frank, Yorktown Heights, NY, United States  
PA Purdue Pharma L.P., Norwalk, CT, United States (U.S. corporation)  
PI US 5958459 19990928  
AI US 1995-561829 19951127 (8)  
RLI Continuation of Ser. No. US 1993-86248, filed on 1 Jul 1993 which is a continuation-in-part of Ser. No. US 1991-814111, filed on 24 Dec 1991, now patented, Pat. No. US 5273760 And a continuation-in-part of Ser. No. US 1995-459110, filed on 2 Jun 1995, now patented, Pat. No. US 5639476 which is a division of Ser. No. US 1993-97558, filed on 27 Jul 1993, now patented, Pat. No. US 5580578 which is a continuation-in-part of Ser. No. US 1992-826084, filed on 27 Jan 1992, now patented, Pat. No. US 5286493  
DT Utility  
FS Granted  
LN.CNT 1241  
INCL INCLM: 424/490.000  
INCLS: 424/458.000; 424/461.000; 424/462.000; 424/480.000; 424/482.000; 424/495.000; 424/497.000; 514/282.000  
NCL NCLM: 424/490.000  
NCLS: 424/458.000; 424/461.000; 424/462.000; 424/480.000; 424/482.000; 424/495.000; 424/497.000; 514/282.000  
IC [6]  
ICM A61K009-14  
ICS A61K009-16; A61K009-36; A61K009-62  
IPCI A61K0009-14 [ICM,6]; A61K0009-16 [ICS,6]; A61K0009-36 [ICS,6]; A61K0009-30 [ICS,6,C\*]; A61K0009-62 [ICS,6]; A61K0009-52 [ICS,6,C\*]  
IPCR A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-30 [I,C\*]; A61K0009-36 [I,A]; A61K0009-52 [I,C\*]; A61K0009-62 [I,A]  
EXF 424/490; 424/495; 424/497; 424/458; 424/461; 424/462; 424/469; 424/480; 424/482; 514/282; 514/289; 514/648  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 63 OF 77 USPATFULL on STN

Full Text

AN 1998:75178 USPATFULL  
TI Sustained release heterodisperse hydrogel systems--amorphous drugs  
IN Baichwal, Anand, Wappingers Falls, NY, United States  
PA Edward Mendell Co., Inc., Patterson, NY, United States (U.S. corporation)  
PI US 5773025 19980630  
AI US 1996-634295 19960418 (8)  
RLI Continuation-in-part of Ser. No. US 1995-447236, filed on 22 May 1995, now patented, Pat. No. US 5554387 which is a division of Ser. No. US 1993-118924, filed on 9 Sep 1993, now patented, Pat. No. US 5455046  
DT Utility  
FS . Granted  
LN.CNT 1710  
INCL INCLM: 424/458.000  
INCLS: 424/452.000; 424/459.000; 424/468.000; 424/476.000; 424/500.000; 514/782.000  
NCL NCLM: 424/458.000  
NCLS: 424/452.000; 424/459.000; 424/468.000; 424/476.000; 424/500.000; 514/782.000  
IC [6]  
ICM A61K009-22  
ICS A61K047-30  
IPCI A61K0009-22 [ICM,6]; A61K0047-30 [ICS,6]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A]; C08J0003-02 [I,C\*]; C08J0003-075 [I,A]  
EXF 424/468; 424/458  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 77 USPATFULL on STN

Full Text

AN 96:77570 USPATFULL  
TI Controlled release oxycodone compositions  
IN Oshlack, Benjamin, New York, NY, United States  
Chasin, Mark, Manalpan, NJ, United States  
Minogue, John J., Mount Vernon, NY, United States  
Kaiko, Robert F., Weston, CT, United States  
PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)  
PI US 5549912 19960827  
WO 9310765 19930610  
AI US 1993-81302 19930618 (8)  
WO 1992-US10146 19921125  
19930618 PCT 371 date  
19930618 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1991-800549, filed on 27 Nov 1991,  
now patented, Pat. No. US 5266331  
DT Utility  
FS Granted  
LN.CNT 1054  
INCL INCLM: 424/468.000  
INCLS: 424/469.000; 424/470.000; 424/486.000; 424/487.000; 424/488.000;  
424/494.000; 424/496.000; 424/497.000; 424/498.000; 424/501.000;  
424/502.000; 424/495.000  
NCL NCLM: 424/468.000  
NCLS: 424/469.000; 424/470.000; 424/486.000; 424/487.000; 424/488.000;  
424/494.000; 424/495.000; 424/496.000; 424/497.000; 424/498.000;  
424/501.000; 424/502.000  
IC [6]  
ICM A61K009-22  
ICS A61K009-26  
IPCI A61K0009-22 [ICM,6]; A61K0009-26 [ICS,6]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
A61K0009-26 [I,C\*]; A61K0009-26 [I,A]; A61K0009-28 [I,C\*];  
A61K0009-28 [I,A]; A61K0009-30 [I,C\*]; A61K0009-30 [I,A];  
A61K0009-52 [I,C\*]; A61K0009-58 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A];  
A61K0047-32 [I,C\*]; A61K0047-32 [I,A]; A61K0047-38 [I,C\*];  
A61K0047-38 [I,A]; A61P0025-00 [I,C\*]; A61P0025-04 [I,A]  
EXF 424/486; 424/468-470; 424/487-88; 424/494; 424/496-498; 424/464-469  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 77 USPATFULL on STN

Full Text

AN 95:84208 USPATFULL  
TI Sustained release matrix system using hydroxyethyl cellulose and  
hydroxypropyl cellulose polymer blends  
IN Rencher, William F., 9455 Misty Grove Cove, Cardova, TN, United States  
38018  
Babu, Suresh, 6 Upper Field Rd., Morristown, NJ, United States 07960  
Musunuri, Shankar, 7565 Charmant Dr., #508, San Diego, CA, United States  
92122  
Day, Christopher H., 237 Bridge St., Spring City, PA, United States  
19475  
Schwing, James, 304 Central Ave., Langhorne Manor, PA, United States  
19047  
PI US 5451409 19950919  
AI US 1993-156223 19931122 (8)  
DT Utility  
FS Granted  
LN.CNT 726  
INCL INCLM: 424/468.000  
INCLS: 424/469.000; 424/480.000; 424/484.000; 424/488.000; 424/494.000;  
514/963.000; 514/964.000; 514/965.000  
NCL NCLM: 424/468.000  
NCLS: 424/469.000; 424/480.000; 424/484.000; 424/488.000; 424/494.000;  
514/963.000; 514/964.000; 514/965.000  
IC [6]  
ICM A61K009-22  
IPCI A61K0009-22 [ICM,6]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];

A61K0009-22 [I,A]; A61K0009-24 [I,C\*]; A61K0009-24 [I,A]  
EXF 424/468; 424/469; 424/480; 424/484; 424/488; 424/494; 514/963; 514/964;  
514/965  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 77 USPATFULL on STN

Full Text

AN 93:100507 USPATFULL  
TI Controlled release oxycodone compositions  
IN Oshlack, Benjamin, New York, NY, United States  
Minogue, John J., Mount Vernon, NY, United States  
Chasin, Mark, Manalpan, NJ, United States  
PA Euroceltique, S.A., Luxembourg (non-U.S. corporation)  
PI US 5266331 19931130  
AI US 1991-800549 19911127 (7)  
DT Utility  
FS Granted  
LN.CNT 677  
INCL INCLM: 424/468.000  
INCLS: 424/469.000; 424/470.000; 424/486.000; 424/487.000; 424/488.000;  
424/494.000; 424/496.000; 424/497.000; 424/498.000; 424/501.000;  
424/502.000; 424/495.000  
NCL NCLM: 424/468.000  
NCLS: 424/469.000; 424/470.000; 424/486.000; 424/487.000; 424/488.000;  
424/494.000; 424/495.000; 424/496.000; 424/497.000; 424/498.000;  
424/501.000; 424/502.000  
IC [5]  
ICM A61K009-22  
ICS A61K009-26  
IPCI A61K0009-22 [ICM,5]; A61K0009-26 [ICS,5]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
A61K0009-26 [I,C\*]; A61K0009-26 [I,A]; A61K0009-28 [I,C\*];  
A61K0009-28 [I,A]; A61K0009-30 [I,C\*]; A61K0009-30 [I,A];  
A61K0009-52 [I,C\*]; A61K0009-58 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A];  
A61K0047-32 [I,C\*]; A61K0047-32 [I,A]; A61K0047-38 [I,C\*];  
A61K0047-38 [I,A]; A61P0025-00 [I,C\*]; A61P0025-04 [I,A]  
EXF 424/464; 424/465; 424/468; 424/469; 424/470; 424/486; 424/487; 424/488;  
424/494; 424/496; 424/497; 424/498  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 67 OF 77 USPATFULL on STN

Full Text

AN 90:25571 USPATFULL  
TI Novel controlled release dosage form of valproic acid  
IN Friedman, Michael, 11 Ejn Gedi Street, Jerusalem, Israel  
Bialer, Meir, 36 Hachalutz Street, Jerusalem, Israel  
Rubinstein, Avraham, 24 Nahage Hapredot St., Jerusalem, Israel  
Dufrovsky, Upd, 24 Yehuda Hanassi Street, Tel-Aviv, Israel  
PI US 4913906 19900403  
AI US 1986-832244 19860224 (6)  
PRAI IL 1985-74468 19850228  
DT Utility  
FS Granted  
LN.CNT 366  
INCL INCLM: 424/499.000  
INCLS: 424/469.000; 424/480.000; 424/482.000  
NCL NCLM: 424/499.000  
NCLS: 424/469.000; 424/480.000; 424/482.000  
IC [4]  
ICM A61K009-50  
IPCI A61K0009-50 [ICM,4]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0031-185 [I,C\*];  
A61K0031-19 [I,A]; A61K0031-20 [I,A]; A61K0031-21 [I,C\*];  
A61K0031-22 [I,A]  
EXF 424/469; 424/480; 424/482; 424/486; 424/464; 424/468; 424/474; 424/475;  
424/477; 424/478  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 77 USPATFULL on STN

Full Text

AN 89:53899 USPATFULL  
 TI Controlled release hydromorphone composition  
 IN Goldie, Robert S., Comberton, England  
 Malkowska, Sandra T. A., Landbeach, England  
 Leslie, Stewart T., Cambridge, England  
 Miller, Ronald B., Basel, Switzerland  
 PA Euroceltique, S.A., Luxemburg, Luxembourg (non-U.S. corporation)  
 PI US 4844909 19890704  
 AI US 1987-113865 19871026 (7)  
 PRAI GB 1986-26098 19861031  
 DT Utility  
 FS Granted  
 LN.CNT 506  
 INCL INCLM: 424/480.000  
 INCLS: 424/484.000; 424/488.000; 424/493.000; 424/494.000; 424/495.000;  
 424/498.000  
 NCL NCLM: 424/480.000  
 NCLS: 424/484.000; 424/488.000; 424/493.000; 424/494.000; 424/495.000;  
 424/498.000  
 IC [4]  
 ICM A61K009-36  
 IPCI A61K0009-36 [ICM,4]; A61K0009-30 [ICM,4,C\*]  
 IPCR A61K0009-28 [I,C\*]; A61K0009-28 [I,A]; A61K0009-16 [I,C\*];  
 A61K0009-16 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-30 [I,C\*];  
 A61K0009-36 [I,A]; A61K0009-50 [I,C\*]; A61K0009-50 [I,A];  
 A61K0031-485 [I,C\*]; A61K0031-485 [I,A]; A61K0047-00 [I,C\*];  
 A61K0047-00 [I,A]; A61K0047-38 [I,C\*]; A61K0047-38 [I,A]  
 EXF 424/480; 424/484; 424/488; 424/493; 424/494; 424/495; 424/498  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 69 OF 77 USPATFULL on STN

Full Text

AN 88:65537 USPATFULL  
 TI Controlled-release dosage form comprising acetaminophen, pseudoephedrine  
 and dexbrompheniramine  
 IN Vadino, Winston A., Whitehouse Station, NJ, United States  
 PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)  
 PI US 4777050 19881011  
 AI US 1987-29032 19870323 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 316  
 INCL INCLM: 424/468.000  
 INCLS: 424/436.000; 424/480.000; 424/488.000; 424/493.000; 424/499.000;  
 514/781.000  
 NCL NCLM: 424/468.000  
 NCLS: 424/436.000; 424/480.000; 424/488.000; 424/493.000; 424/499.000;  
 514/781.000  
 IC [4]  
 ICM A61K031-74  
 ICS A61K009-20; A61K009-22  
 IPCI A61K0031-74 [ICM,4]; A61K0009-20 [ICS,4]; A61K0009-22 [ICS,4]  
 IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A];  
 A61K0031-44 [I,C\*]; A61K0031-44 [I,A]  
 EXF 424/468; 424/436; 424/480; 424/488; 424/493; 424/499; 514/781  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 70 OF 77 USPATFULL on STN

Full Text

AN 87:26265 USPATFULL  
 TI Controlled release dosage form comprising acetaminophen, pseudoephedrine  
 sulfate and dexbrompheniramine maleate  
 IN Hanna, Gayda, Berwyn, PA, United States  
 Vadino, Winston A., Bridgewater, NJ, United States  
 PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)  
 PI US 4657757 19870414  
 AI US 1985-804707 19851204 (6)  
 RLI Continuation-in-part of Ser. No. US 1985-718036, filed on 29 Mar 1985,  
 now patented, Pat. No. US 4601894  
 DT Utility

FS Granted  
LN.CNT 324  
INCL INCLM: 424/488.000  
INCLS: 514/781.000  
NCL NCLM: 424/488.000  
NCLS: 514/781.000  
IC [4]  
ICM A61K009-22  
ICS A61K009-26  
IPCI A61K0009-22 [ICM,4]; A61K0009-26 [ICS,4]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0031-44 [I,C\*]; A61K0031-44 [I,A]  
EXF 424/14-22; 424/35; 514/781  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 71 OF 77 USPAT2 on STN

Full Text

AN 2003:311886 USPAT2  
TI Once-a-day controlled release sulfonylurea formulation  
IN Bhagwat, Dileep, Bronxville, NY, United States  
Diehl, II, Donald, Stony Point, NY, United States  
Baichwal, Anand R., Wappinger Falls, NY, United States  
PA Penwest Pharmaceuticals Co., Patterson, NY, United States (U.S. corporation)  
PI US 6875793 B2 20050405  
AI US 2003-396114 20030325 (10)  
RLI Continuation of Ser. No. US 2000-479465, filed on 7 Jan 2000, now patented, Pat. No. US 6537578 Continuation of Ser. No. US 1997-950732, filed on 15 Oct 1997, now patented, Pat. No. US 6056977  
DT Utility  
FS GRANTED  
LN.CNT 1357  
INCL INCLM: 514/593.000  
INCLS: 514/255.060; 514/866.000  
NCL NCLM: 514/593.000; 424/468.000  
NCLS: 514/255.060; 514/866.000; 514/054.000; 514/369.000  
IC [7]  
ICM A61K031-4965  
ICS A61K031-64; A61P005-30  
IPCI A61K0031-426 [ICM,7]; A61K0009-22 [ICS,7]  
IPCI-2 A61K0031-4965 [ICM,7]; A61K0031-64 [ICS,7]; A61P0005-30 [ICS,7];  
A61P0005-00 [ICS,7,C\*]  
IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-28 [N,C\*]; A61K0009-28 [N,A];  
A61K0031-64 [I,C\*]; A61K0031-64 [I,A]; A61P0005-00 [I,C\*];  
A61P0005-30 [I,A]  
EXF 424/488; 424/468; 424/499; 424/500; 424/485; 424/458; 514/255.06;  
514/593; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 77 USPAT2 on STN

Full Text

AN 2003:37195 USPAT2  
TI Melt-extrusion multiparticulates  
IN Oshlack, Benjamin, New York, NY, United States  
Chasin, Mark, Manalapan, NJ, United States  
Huang, Hua-Pin, Englewood Cliffs, NJ, United States  
PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6706281 B2 20040316  
AI US 2002-38867 20020102 (10)  
RLI Continuation of Ser. No. US 1999-358828, filed on 22 Jul 1999, now patented, Pat. No. US 6335033 Continuation of Ser. No. US 1994-334209, filed on 4 Nov 1994, now patented, Pat. No. US 5965161  
DT Utility  
FS GRANTED  
LN.CNT 966  
INCL INCLM: 424/457.000  
INCLS: 424/456.000; 424/451.000; 424/452.000; 424/489.000; 514/772.300;  
514/772.600; 514/781.000; 514/783.000; 514/784.000; 514/785.000;  
514/786.000; 514/951.000; 514/962.000  
NCL NCLM: 424/457.000; 424/469.000  
NCLS: 424/451.000; 424/452.000; 424/456.000; 424/489.000; 514/772.300;

514/772.000; 514/781.000; 514/783.000; 514/784.000; 514/785.000;  
514/786.000; 514/951.000; 514/962.000; 424/417.000; 504/367.000;  
514/282.000

IC [7]  
ICM A61K009-16  
ICS A61K009-52  
IPCI A01N0025-12 [ICM,7]; A01N0043-42 [ICS,7]; A01N0043-34 [ICS,7,C\*];  
A01N0025-26 [ICS,7]; A61K0009-52 [ICS,7]; A61K0031-485 [ICS,7]  
IPCI-2 A61K0009-16 [ICM,7]; A61K0009-52 [ICS,7]  
IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
A61K0009-20 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]  
EXF 424/457; 424/456; 424/468; 424/489; 424/451; 424/452; 424/488; 424/487  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 73 OF 77 USPAT2 on STN

Full Text

AN 2002:336920 USPAT2  
TI Controlled release hydrocodone formulations  
IN Oshlack, Benjamin, New York, NY, United States  
Masselink, John K., Old Tappan, NJ, United States  
Huang, Hua-Pin, Englewood Cliffs, NJ, United States  
Tonelli, Alfred P., Congers, NY, United States  
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6733783 B2 20040511  
AI US 2001-16651 20011030 (10)  
PRAI US 2000-244424P 20001030 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1743  
INCL INCLM: 424/473.000  
INCLS: 424/457.000; 424/468.000; 424/484.000; 424/485.000; 424/487.000;  
424/488.000; 424/489.000; 424/490.000; 424/472.000  
NCL NCLM: 424/473.000; 424/458.000  
NCLS: 424/457.000; 424/468.000; 424/472.000; 424/484.000; 424/485.000;  
424/487.000; 424/488.000; 424/489.000; 424/490.000; 424/470.000;  
514/282.000

IC [7]  
ICM A61K009-22  
ICS A61K009-24; A61K009-26; A61K009-44; A61K009-52  
IPCI A61K0009-54 [ICM,7]; A61K0009-52 [ICM,7,C\*]; A61K0009-26 [ICS,7];  
A61K0031-485 [ICS,7]  
IPCI-2 A61K0009-22 [ICM,7]; A61K0009-24 [ICS,7]; A61K0009-26 [ICS,7];  
A61K0009-44 [ICS,7]; A61K0009-52 [ICS,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-26 [I,C\*]; A61K0009-26 [I,A];  
A61K0009-52 [I,C\*]; A61K0009-52 [I,A]; A61K0009-54 [I,A];  
A61K0031-485 [I,C\*]; A61K0031-485 [I,A]  
EXF 424/457; 424/458; 424/468; 424/469; 424/473; 424/474; 424/475; 424/476;  
424/477; 424/480; 424/482; 424/472; 424/459  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 77 USPAT2 on STN

Full Text

AN 2002:191239 USPAT2  
TI Stabilized sustained release tramadol formulations  
IN Oshlack, Benjamin, New York, NY, United States  
Huang, Hua-Pin, Englewood Cliffs, NJ, United States  
Chasin, Mark, Manalapan, NJ, United States  
Goldenheim, Paul, Wilton, CT, United States  
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6645527 B2 20031111  
AI US 2001-52844 20011019 (10)  
RLI Continuation of Ser. No. US 1998-109615, filed on 2 Jul 1998, now  
patented, Pat. No. US 6306438  
PRAI US 1997-51602P 19970702 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1661  
INCL INCLM: 424/468.000  
NCL NCLM: 424/468.000  
NCLS: 514/649.000  
IC [7]



ICM A61K009-22  
 IPCI A61K0009-22 [ICM,7]; A61K0031-137 [ICS,7]  
 IPCI-2 A61K0009-22 [ICM,7]  
 IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-26 [I,C\*]; A61K0009-26 [I,A];  
 A61K0009-30 [I,C\*]; A61K0009-42 [I,A]  
 EXF 424/468; 424/469; 424/470; 424/476; 424/484; 424/485; 424/486; 424/487;  
 424/488; 424/400  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 77 USPAT2 on STN

Full Text

AN 2002:54391 USPAT2  
 TI Controlled release dosage form of [R-(Z)]- $\alpha$ -(methoxyimino)- $\alpha$ -  
 (1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride  
 IN Sauer, Joseph Peter, Sarasota, FL, United States  
 Milosovich, Susan Marie, Phoenixville, PA, United States  
 Muldoon, William Thomas, Philadelphia, PA, United States  
 Napper, James Albert, Pound Hill, UNITED KINGDOM  
 Rousseau, Laurence, Broxbourne, UNITED KINGDOM  
 PA SmithKline Beecham p.l.c., Brentford, UNITED KINGDOM (non-U.S.  
 corporation)  
 SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
 corporation)  
 PI US 6468560 B2 20021022  
 AI US 2001-956617 20010919 (9)  
 RLI Continuation of Ser. No. US 2001-759576, filed on 12 Jan 2001  
 Continuation of Ser. No. US 254621, now abandoned  
 PRAI GB 1996-19074 19960912  
 DT Utility  
 FS GRANTED  
 LN.CNT 769  
 INCL INCLM: 424/451.000  
 INCLS: 424/464.000; 424/468.000; 424/489.000; 424/490.000; 424/472.000;  
 424/463.000  
 NCL NCLM: 424/451.000; 424/468.000  
 NCLS: 424/463.000; 424/464.000; 424/468.000; 424/472.000; 424/489.000;  
 424/490.000; 424/469.000  
 IC [7]  
 ICM A61K009-48  
 ICS A61K009-20; A61K009-22; A61K009-14; A61K009-16  
 IPCI A61K0009-22 [ICM,7]; A61K0009-26 [ICS,7]  
 IPCI-2 A61K0009-48 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7];  
 A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]  
 IPCR A61K0009-16 [I,C\*]; A61K0009-16 [I,A]; A61K0009-20 [I,C\*];  
 A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A];  
 A61K0009-26 [I,C\*]; A61K0009-26 [I,A]; A61K0009-50 [I,C\*];  
 A61K0009-50 [I,A]; A61K0031-439 [I,C\*]; A61K0031-439 [I,A]  
 EXF 424/464; 424/468; 424/472; 424/451; 424/489; 424/490; 424/463  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 76 OF 77 USPAT2 on STN

Full Text

AN 2001:218029 USPAT2  
 TI Sustained release heterodisperse hydrogel systems-amorphous drugs  
 IN Baichwal, Anand, Wappingers Falls, NY, United States  
 PA Penwest Pharmaceuticals Co., Patterson, NY, United States (U.S.  
 corporation)  
 PI US 6709677 B2 20040323  
 AI US 2001-879296 20010612 (9)  
 RLI Continuation of Ser. No. US 2000-498448, filed on 4 Feb 2000, now  
 patented, Pat. No. US 6245356 Continuation of Ser. No. US 1998-106438,  
 filed on 29 Jun 1998, now patented, Pat. No. US 6048548 Continuation of  
 Ser. No. US 1996-634295, filed on 18 Apr 1996, now patented, Pat. No. US  
 5773025 Continuation of Ser. No. US 1995-447236, filed on 22 May 1995,  
 now patented, Pat. No. US 5554387 Division of Ser. No. US 1993-118924,  
 filed on 9 Sep 1993, now patented, Pat. No. US 5455046  
 DT Utility  
 FS GRANTED  
 LN.CNT 1553  
 INCL INCLM: 424/489.000  
 INCLS: 424/468.000; 424/481.000; 424/474.000; 424/464.000; 424/490.000;

424/496.000  
 NCL NCLM: 424/489.000; 424/468.000  
 NCLS: 424/464.000; 424/468.000; 424/474.000; 424/481.000; 424/490.000;  
 424/496.000; 424/195.180; 514/355.000  
 IC [7]  
 ICM A61K009-14  
 ICS A61K009-20; A61K009-22; A61K009-16; A61K009-28  
 IPCI A61K0009-22 [ICM,7]; A61K0031-4418 [ICS,7]  
 IPCI-2 A61K0009-14 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7];  
 A61K0009-16 [ICS,7]; A61K0009-28 [ICS,7]  
 IPCR A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A];  
 C08J0003-02 [I,C\*]; C08J0003-075 [I,A]  
 EXF 424/464; 424/468; 424/481; 424/474; 424/489; 424/490; 424/496  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 77 OF 77 USPAT2 on STN.

Full Text

AN 2001:188235 USPAT2  
 TI Melt-extrusion multiparticulates  
 IN Oshlack, Benjamin, New York, NY, United States  
 Huang, Hua-Pin, Englewood Cliffs, NJ, United States  
 Chasin, Mark, Manalapan, NJ, United States  
 PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
 PI US 6335033 B2 20020101  
 AI US 1999-358828 19990722 (9)  
 RLI Continuation of Ser. No. US 1994-334209, filed on 4 Nov 1994, now  
 patented, Pat. No. US 5965161  
 DT Utility  
 FS GRANTED  
 LN.CNT 1000  
 INCL INCLM: 424/457.000  
 INCLS: 424/451.000; 424/452.000; 424/456.000; 424/489.000; 424/488.000;  
 424/487.000; 514/772.600; 514/781.000; 514/784.000; 514/785.000;  
 514/786.000; 514/951.000; 514/962.000  
 NCL NCLM: 424/457.000  
 NCLS: 424/451.000; 424/452.000; 424/456.000; 424/487.000; 424/488.000;  
 424/489.000; 514/772.600; 514/781.000; 514/784.000; 514/785.000;  
 514/786.000; 514/951.000; 514/962.000  
 IC [7]  
 ICM A61K009-16  
 ICS A61K009-52  
 IPCI A61K0009-52 [ICM,7]  
 IPCI-2 A61K0009-16 [ICM,7]; A61K0009-52 [ICS,7]  
 IPCR A61K0009-14 [N,C\*]; A61K0009-14 [N,A]; A61K0009-16 [I,C\*];  
 A61K0009-16 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A];  
 A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-52 [I,C\*];  
 A61K0009-52 [I,A]; A61K0031-135 [I,C\*]; A61K0031-135 [I,A];  
 A61K0031-485 [I,C\*]; A61K0031-485 [I,A]  
 EXF 424/457; 424/458; 424/489; 424/456; 424/468; 424/451; 424/452; 424/486;  
 424/487; 424/488  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti in pa pi kwic 64 66 68 69 73

L6 ANSWER 64 OF 77 USPATFULL on STN

Full Text

AN 96:77570 USPATFULL  
 TI Controlled release oxycodone compositions  
 IN Oshlack, Benjamin, New York, NY, United States  
 Chasin, Mark, Manalpan, NJ, United States  
 Minogue, John J., Mount Vernon, NY, United States  
 Kaiko, Robert F., Weston, CT, United States  
 PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)  
 PI US 5549912 19960827  
 WO 9310765 19930610  
 CLM What is claimed is:  
 3. A solid **controlled release oral dosage form**, comprising (a)  
 oxycodone or a salt thereof in an amount from about 10 to about 160 mg;  
 (b) an effective.  
 5. A solid **controlled release oral dosage form**, comprising (a)

an analgesically effective amount of spheroids comprising oxycodone or a salt thereof and either a spheronising agent or an acrylic **polymer** or copolymer, such that the total dosage of oxycodone in said dosage form is from about 10 to about 160. . .

L6 ANSWER 66 OF 77 USPATFULL on STN

Full Text

AN 93:100507 USPATFULL  
TI Controlled release oxycodone compositions  
IN Oshlack, Benjamin, New York, NY, United States  
Minogue, John J., Mount Vernon, NY, United States  
Chasin, Mark, Manalpan, NJ, United States  
PA Euroceltique, S.A., Luxembourg (non-U.S. corporation)  
PI US 5266331 19931130  
CLM What is claimed is:  
1. A solid, **controlled release, oral dosage form**, the dosage form comprising an analgesically effective amount of oxycodone or a salt thereof in a matrix wherein the dissolution. . .  
7. A solid **controlled release oral dosage form**, comprising an analgesically (a) effective amount of oxycodone or a salt thereof; (b) an effective amount of a controlled release. . .  
10. A solid **controlled release oral dosage form**, comprising (a) an analgesically effective amount of spheroids comprising oxycodone or a salt thereof and either a spheronising agent or an acrylic **polymer** or copolymer; (b) a film coating which controls the release of the oxycodone or oxycodone salt at a controlled rate. . .  
14. A process for the preparation of a solid, **controlled release, oral dosage form** comprising incorporating an analgesically effective amount of oxycodone or a salt thereof in a controlled release matrix comprising from about. . .

L6 ANSWER 68 OF 77 USPATFULL on STN

Full Text

AN 89:53899 USPATFULL  
TI Controlled release hydromorphone composition  
IN Goldie, Robert S., Comberton, England  
Malkowska, Sandra T. A., Landbeach, England  
Leslie, Stewart T., Cambridge, England  
Miller, Ronald B., Basel, Switzerland  
PA Euroceltique, S.A., Luxemburg, Luxembourg (non-U.S. corporation)  
PI US 4844909 19890704  
CLM What is claimed is:  
1. A solid, **controlled release, oral dosage form**, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix, comprising at least. . .  
14. A solid **controlled release, oral dosage form**, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution. . .  
16. A dosage form according to claim 15 wherein the spheroid matrix comprises microcrystalline cellulose and a water insoluble **polymer**.  
  
17. A solid, **controlled release, oral dosage form** comprising film coated spheroids, the spheroids comprising a therapeutically effective amount of hydromorphone or a salt thereof incorporated in a.

L6 ANSWER 69 OF 77 USPATFULL on STN

Full Text

AN 88:65537 USPATFULL  
TI Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dextbrompheniramine  
IN Vadino, Winston A., Whitehouse Station, NJ, United States  
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)  
PI US 4777050 19881011  
CLM What is claimed is:  
1. A **controlled-release oral dosage form** comprising an analgesic-effective amount of acetaminophen, an amount of pseudoephedrine or a pharmaceutically acceptable salt thereof effective in reducing nasal. . . dextbrompheniramine or a pharmaceutically acceptable salt thereof in a single homogeneous matrix, said matrix comprising either (1) a single cellulosic **polymer** selected from the group consisting of methylcellulose, hydroxypropylcellulose,

hydroxymethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, carboxyethylcellulose, sodium carboxymethylcellulose and sodium carboxyethylcellulose; (2) a mixture of said cellulosic, polymers; or (3) said cellulosic **polymer** or a mixture of said cellulosic polymers and 1 to 45% by weight of the **polymer** mixture of ethylcellulose or other cellulose ethers or combinations thereof, wherein said single cellulosic **polymer** or mixture of cellulosic polymers constitutes 1-8% by weight of the uncoated dosage form, or wherein the **polymer** mixture comprising the cellulose ether constitutes 8-15% by weight of the uncoated dosage form.

5. A dosage form of claim 4 comprising 100% cellulosic **polymer**, wherein the total **polymer** weight represents 1-8% of the total dosage form weight, the total filler weight represents 10-13% of the total dosage-form weight, . . . .

6. A dosage form of claim 5 wherein the **polymer** is 100% hydroxypropylcellulose.

7. A dosage form of claim 5 wherein the **polymer** is 100% hydroxyethylcellulose.

10. A dosage form of claim 5 comprising 1-8% cellulosic **polymer**, 10-13% dibasic calcium phosphate dihydrate and 1-3% of a combination of stearic acid and magnesium stearate.

15. A dosage form of claim 4 wherein the **polymer** comprises 99-55% cellulosic **polymer** and 1-45% ethylcellulose, the total **polymer** weight represents 10-15% of the total dosage form weight, the total filler weight represents 10-13% of the total dosage form. . . .

16. A dosage form of claim 15 wherein the **polymer** is 66.5-55% cellulosic **polymer** and 33.5-45% ethylcellulose.

19. A dosage form of claim 15 comprising 66.5-55% cellulosic **polymer**, 33.5-45% ethylcellulose, 10-13% dibasic calcium phosphate dihydrate and 1-3% of a combination of stearic acid and magnesium stearate.

L6 ANSWER 73 OF 77 USPAT2 on STN

Full Text

AN 2002:336920 USPAT2

TI Controlled release hydrocodone formulations

IN Oshlack, Benjamin, New York, NY, United States

Masselink, John K., Old Tappan, NJ, United States

Huang, Hua-Pin, Englewood Cliffs, NJ, United States

Tonelli, Alfred P., Congers, NY, United States

PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)

PI US 6733783 B2 20040511

CLM What is claimed is:

27. A **sustained release oral dosage form** comprising: (a) a bilayer core comprising: (i) a drug layer comprising an analgesically effective amount of hydrocodone or a pharmaceutically. . . .

37. A **sustained release oral dosage form** comprising: (a) a bilayer core comprising: (i) a drug layer comprising an analgesically effective amount of hydrocodone or a pharmaceutically. . . .

39. The controlled release dosage form claim 1, wherein said controlled release material is a hydrophobic **polymer** selected from the group consisting of alkylcelluloses and acrylic resins.

. . . controlled release dosage form of claim 18, wherein said hydrophobic material is selected from the group consisting of a cellulosic **polymer**, an acrylic **polymer**, and mixtures thereof.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

112.87

113.08

STN INTERNATIONAL LOGOFF AT 20:56:32 ON 20 NOV 2007